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INTRODUCTION 
 
The cells within a multicellular organism (metazoan) must communicate with each 
other to coordinate their functions. Cell adhesion is not only a fundamental prerequisite for 
functions, such as the organization of tissues and organs, but also a critical way for the 
metazoan to communicate with its environment, such as host defence response to certain 
microorganisms. On the molecular level, cell adhesion depends on combinatorial expression 
and interactions of a large, but limited, number of adhesion receptors. In addition to their roles 
in binding cells to other cells or to extracellular matrices (ECM), engagement of cell adhesion 
receptors has major effects on many aspects of cell behavior, such as cell morphology and 
motility, cell proliferation and differentiation, and cell survival.    
So far four major classes of cell adhesion receptors have been described: cadherins, 
immunoglobulin superfamily (IgSF) members, selectins, and integrins (reviewed by Hynes, 
1999). Many of these cell adhesion receptors, in particular integrins, members of IgSF, and 
selectins, play important roles in the immune system, where they mediate leukocyte adhesion 
and adhesion-dependent functions, such as cytotoxicity of T lymphocytes, natural killer cells, 
and lymphokine-activated killer cells, immunoglobulin (Ig) synthesis of B lymphocytes, and 
homing of leukocytes to various organs. Meanwhile, some of the cell adhesion receptors, such 
as members of IgSF, integrins, and cadherins, are important in the nervous system, where they 
mediate neuronal migration, axonal elongation and fasciculation, synpatogenesis and synaptic 
plasticity.  
IgSF numbers well over 100 members in vertebrates. It is characterized by the 
presence of varying numbers of Ig domains, sometimes followed by fibronectin type III 
(FnIII) domains. Within this superfamily, intercellular adhesion molecules (ICAMs) form a 
major subgroup which participate in leukocyte adhesion through binding to the leukocyte-
specific β2 integrins, whereas neural cell adhesion molecule (NCAM), L1, and their related 
molecules comprise another major subgroup, which functions in neuronal activity through 
homophilic or heterophilic interactions. Notably, some IgSF members, such as L1, play roles 
both in the immune and nervous systems. 
In this thesis, a main focus is placed on the molecular analysis of a novel member of 
ICAM subfamily, ICAM-5 (telencephalin). Characterizations of its heterophilic interaction 
with the β2 integrin CD11a/CD18 (LFA-1), and homophilic interaction with itself are 
described in the original publications. Its possible functions in the nervous system are 
discussed.           
 
 
 
  9 
REVIEW OF THE LITERATURE 
 
1. LEUKOCYTE ADHESION 
 
Leukocytes, i.e., granulocytes, monocytes/macrophages, and lymphocytes, are bone 
marrow-derived cells of diverse form and function, which circulate in the blood in a low 
adhesive state before migrating into tissues. They are important in the defence against 
invading microbes, and participate in immune functions and wound repair. Adhesion to other 
cells and to the ECM is a fundamental feature of leukocyte physiology, a process crucial to 
the generation of immune responses. An important prerequisite for an inflammatory response 
to occur is the trafficking of leukocytes, from the blood to the site of inflammation. This 
process has been studied extensively, and many molecules responsible for leukocyte adhesion 
and concurrent extravasation have been characterized. 
According to the current concept, three major families of leukocyte adhesion 
molecules, namely integrins, members of the immunoglobulin superfamily, and selectins act 
in concert to facilitate migration of leukocytes from blood to extravascular sites of 
inflammation. Nevertheless, there are also other adhesion molecules involved in this process 
(reviewed by Carlos and Harlan, 1994; Dianzani and Malavasi, 1995; Gahmberg et al., 1998).  
Leukocyte traffic is dynamic and involves multiple steps (reviewed by Butcher, 1992) 
(Fig. 1). In each step a different family of adhesion molecules takes part. Circulating 
leukocytes are initially tethered loosely to endothelium through interaction of selectins on 
leukocytes or endothelial cells with their glycoconjugate ligands. These selectin-mediated 
cell-cell interactions cause leukocytes to roll on endothelium. Upon activation by cell-
associated or soluble mediators of inflammation, loosely adherent rolling leukocytes are 
immobilized on endothelium through interaction of integrins expressed on leukocytes with 
endothelial counter-receptors, many of which are members of the IgSF. The final step of 
transendothelial migration is, again, mediated mainly by these two families of adhesion 
molecules. 
Some novel phenomena discovered in leukocyte recruitment are also noteworthy. For 
example, activated platelets can form a cellular bridge for lymphocyte rolling on high 
endothelial vanules (Diacovo et al., 1996), mediated by platelet-expressed P-selectin binding 
to P-selectin glycoprotein ligand-1 (PSGL-1) on lymphocytes. This enables lymphocytes to 
undergo subsequent β2 integrin-dependent firm adhesion (reviewed by von Andrian and 
M’Rini, 1998). Another interesting phenomenon is a novel pathway provided by fibrinogen, 
which may form a bridge between leukocytes and endothelial cells through its binding to 
ICAM-1, and thus may act in concert with β2 integrins to stabilize firm leukocyte attachment 
to and extravasation from endothelium (reviewed by Altieri, 1999). These data make the 
leukocyte traffic more complex and dynamic than earlier believed. 
 
1.1. Families of adhesion molecules 
 
1.1.1. Leukocyte integrins 
 
INTRODUCTION. Integrins comprise a large family of cell surface receptors that are 
found in many species, ranging from sponges to mammals. Found in the 1980s, integrins are 
so named due to their fundamental roles in integrating signals between the extracellular 
matrix on the exterior of cells and the cytoskeleton on the interior (Hynes, 1987). Integrins are 
important because they play key roles in cell adhesion, cell migration, cell differentiation and 
proliferation, and programmed cell death (recently reviewed by Coppolino and Dedhar, 
2000). 
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 Figure 1. Multi-step leukocyte trafficking through endothelium. 
 
Integrins are heterodimeric molecules comprised of one each of the 18 known α 
subunits and the 8 known β subunits by noncovalent association. At least 20 distinct human 
heterodimers have been so far discovered (Fig. 2A). They recognize a variety of ligands 
including ECM proteins, cell surface proteins, and plasma proteins (reviewed by Hemler, 
1999).  
In leukocytes, at least 13 different integrins are expressed, belonging to β1, β2, β3, or 
β7 subfamilies (reviewed by Harris et al., 2000; Shimizu et al., 1999; Stewart et al., 1995) 
(Table 1). Among them, β2 and β7 are leukocyte-specific integrins, while β1 and β3 integrins 
are also found in other cell types. In this review, I will focus on β2 integrins, while the other 
integrins will only be briefly described. 
β1 integrins is a large integrin subfamily which binds to many ECM components as 
well as to certain cellular ligands. They are widely expressed and perform broad functions. 
Some β1 integrins are also found in leukocytes, and perhaps the most important one is very 
late antigen-4 (VLA-4, α4β1, CD49d/CD29) (Adams and Lobb, 1999). VLA-4 binds to 
fibronectin and vascular cell adhesion molecule-1 (VCAM-1, CD106) (Elices et al., 1990). 
Unlike many other leukocyte integrins, VLA-4 has been shown to mediate leukocyte 
tethering, rolling, and firm adhesion on endothelium, as well as transendothelial migration 
(Berlin et al., 1995).        
αVβ3 (CD51/CD61) is another integrin expressed mainly in non-haematopoetic cells, 
but recently implicated in leukocyte adhesion through its binding to platelet endothelial cell 
adhesion molecule-1 (PECAM-1) (Piali et al., 1995).  
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β7 integrins are composed of two heterodimers with a common β7 subunit 
noncovalently associated with either the α4 or the αE subunits. α4β7 binds to mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1) (Berlin et al., 1993), VCAM-1, and 
fibronectin (Ruegg et al., 1992). αEβ7 binds to E-cadherin (Cepek et al., 1994). Binding of 
α4β7 to MAdCAM-1 is involved in homing of naïve lymphocytes to Peyer’s patches, 
whereas interaction of αEβ7 with E-cadherin is required for retention of lymphocytes within 
the epithelium. 
 
α1
α2
α3
α4
α5
α6
α7
α8
α9
α10
α11
αV
 
 
 
β7
β4
β3
β5
β6
β8
αΕ
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α
α
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I II III IV V VI VIIα
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Figure 2. The integrin subfamilies. A shows the possible combinations of different 
α and β chains found so far. The pairs marked with heavy lines have a leukocyte-
specific expression. B shows the schematic primary structures of integrin α and β 
chains. 
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It is noteworthy that αV,α4, and αE (CD103) integrins are structurally quite different 
from the α subunits of β2 integrins. αV integrin lacks an I (A) domain, but has a disulfide-
linked cleavage site towards the carboxyl terminus of the extracellular domain. Whereas α4 
integrins have neither an I domain nor a disulfide-linked cleavage site, αE integrin has both 
(Hemler, 1999) (Fig. 2B). 
β2 integrins are restricted solely to leukocytes, and thus are usually called “leukocyte 
integrins” (reviewed by Harris et al., 2000; Gahmberg et al., 1998). They are also often 
referred to as CD11/CD18 integrins by using the Cluster of Differentiation (CD) 
nomenclature. Up to date, there are four β2 integrins described, namely CD11a/CD18 (αLβ2, 
LFA-1), CD11b/CD18 (αMβ2, Mac-1, CR3), CD11c/CD18 (αXβ2, p150,95, CR4), and 
CD11d/CD18 (αDβ2). The genes encoding the α (CD11) subunits are localized to 
chromosome 16 and the gene encoding β (CD18) subunit to chromosome 21 (reviewed by 
Hemler, 1999).  
 
STRUCTURE. During biosynthesis, α and β subunits noncovalently associate within 
intracellular compartments prior to transportation to the cell surface. All the β2 integrin 
subunits are heavily N-glycosylated in their extracellular domains (reviewed by Gahmberg et 
al., 1997b). The structures of the oligosaccharides have been reported to contain SLe
x
 which 
is usually recognized by selectins (Asada et al., 1991). 
Electron microscopy studies suggest that an intact integrin may have a globular head 
region, supported by two stalks (Nermut et al., 1988). General structural features of β2 
integrins are shown in Fig. 3. The CD11b, c, and d subunits show 60-66% identity to each 
other and are 35-36% identical to CD11a. The CD11a (180 kDa), b (170 kDa), c (150 kDa), 
and d (155 kDa) subunits all have seven amino terminal repeating segments that may fold into 
a seven-unit β-propeller motif, resembling that found in G protein β subunits (reviewed by 
Springer, 1997) (Fig. 3). Each has three typical EF-hand type cation-binding sites in the 
amino-terminal repeating units 5 to 7 (Fig. 3A). They also contain I domains of about 200 
amino acids between repeating units 2 and 3, that play essential roles during ligand binding 
(reviewed by Dickeson and Santoro, 1998) (Fig. 3B and C). 
Recombinant I domains from CD11b (Lee et al., 1995b) and CD11a (Qu and Leahy, 
1995) have been crystallized. Both have a Rossmann fold pattern, with a divalent cation 
coordination site (metal ion-dependent adhesion site, MIDAS motif) on the surface. Whereas 
the CD11b I domain structure may vary depending on the presence of Mn
2+
 or Mg
2+
 (Lee et 
al., 1995a), the CD11a I domain structure is essentially unchanged with or without Mn
2+
 or 
Mg
2+
 (Qu and Leahy, 1995). However, later studies do suggest a comformational change of 
CD11a I domain after ligand binding (Huth et al., 2000; McDowall et al., 1998). 
The CD18 subunit is more similar to β7 and β1 (46% identity) than to other β 
subunits. It contains 56 extracellular cysteines conserved in β1, β3, β5 and β6 subunits, and a 
typical four-fold repeat in the cysteine-rich region (Fig. 3A). Recent findings suggest that the 
CD18 subunit contains a 241 amino acid I-like domain near the amino-terminus, which 
associates with the β-propeller domain of the CD11 subunit (Zang et al., 2000) (Fig. 3B). 
Residues within the CD18 MIDAS motif of the I-like domain are thought to be important in 
ligand binding (Goodman and Bajt, 1996). 
The cytoplasmic tails (19-53 residues) of CD11 subunits are substantially more 
dissimilar than the rest of these molecules. They contain a GFFKR motif proximal to the 
transmembrane domains, which is conserved in all integrin α chains, and is considered to 
form a hinge with the corresponding regions of β subunit cytoplasmic tails to lock the 
heterodimers into a low affinity conformation in the absence of activating signals (reviewed 
by van Kooyk et al., 1998). It is also involved in subunit dimerization (Pardi et al., 1995). The 
  13 
CD18 cytoplasmic tail contains an NPXF instead of NPXY motif found in β1, β3, β5, β6, and 
β7 which may be important for integrin localization, endocytosis, and signaling (van Kooyk et 
al., 1998). Besides, the SXXTT motif in the CD18 cytoplasmic tail is also conserved in β1 
and β7 (reviewed by van Kooyk et al., 1998; Ylänne, 1998), and mutation of threonines to 
alanines abolishes the binding of CD11a/CD18 to ICAM-1 (Hibbs et al., 1991).  
 
Integrins in the immune system  
Table 1. Integrins in the immune system. The integrins, their major cellular 
expressions, and their ligands are listed. 
 
The β2 integrin cytoplasmic tails have several putative phosphorylation sites. The 
CD11 chains are constitutively phosphorylated, whereas the CD18 chain is phosphorylated 
only after activation, and the phosphorylation occurs in the SXXTT motif as mentioned above 
(Hibbs et al., 1991; Valmu and Gahmberg, 1995). Whether the phosphorylation of β2 
integrins is important for regulation of integrin activity remains unclear, however, recent 
studies indicate the involvement of CD18 phosphorylation in cytoskeletal protein binding and 
increased avidity of β2 integrins (Valmu et al., 1999 a and b; reviewed by van Kooyk et al., 
1998). 
  
EXPRESSION AND LIGANDS. CD11a/CD18 is present on nearly all leukocytes. In 
contrast, CD11b/CD18 and CD11c/CD18 are found on monocytes, macrophages, 
granulocytes, large granular lymphocytes, and a subpopulation of immature B cells. 
 
INTEGRINS 
 
 
 
MAJOR 
EXPRESSION 
 
THEIR LIGANDS 
β2 integrins 
CD11a/CD18 (αLβ2, LFA-1) 
CD11b/CD18 (αMβ2, Mac-1, CR3) 
 
 
CD11c/CD18 (αXβ2, p150,95, CR4) 
 
CD11d/CD18 (αDβ2) 
 
Lymphocytes 
Granulocytes 
 
 
Monocytes/ 
Macrophages 
Macrophages 
(spleen) 
 
ICAM-1-5, Collagens 
ICAM-1, -2, -4, E-selectin, 
iC3b, Fibrinogen, Factor X, 
Heparin, etc. 
ICAM-1, iC3b, Fibrinogen, 
Collagens 
ICAM-3, VCAM-1 
β7 integrins 
α4β7 
 
αEβ7 
 
 
Lymphocytes 
(lymph nodes) 
Lymphocytes 
(intraepithelia) 
 
MAdCAM-1, VCAM-1, 
Fibronectin 
E-Cadherin 
β1 integrins 
α1β1 (VLA-1, CD49a/CD29) 
α2β1 (VLA-2, CD49b/CD29) 
α3β1 (VLA-3, CD49c/CD29) 
α4β1 (VLA-4, CD49d/CD29) 
α5β1 (VLA-5, CD49e/CD29) 
α6β1 (VLA-6, CD49f/CD29) 
 
Lymphocytes 
Lymphocytes 
Lymphocytes 
Lymphocytes 
Lymphocytes 
Lymphocytes 
 
Collagens, Laminins 
Collagens, Laminins 
Laminins 
VCAM-1, Fibronectin 
Fibronectin 
Laminins, Fertilin 
β3 integrins 
αVβ3 (CD51/CD61) 
 
Macrophages 
 
PECAM-1, Fibrinogen, 
Fibronectin, Vitronectin, etc. 
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CD11c/CD18 is also found on some activated lymphocytes and monocytes, and is a marker 
for hairy cell leukemia (reviewed by Hemler, 1999). CD11d/CD18 is less expressed on 
peripheral blood leukocytes, but is highly expressed on tissue-compartmentalized 
macrophages and related cells (Grayson et al., 1999) (Table 1).  
 
I II III IV V VI VIII domain
7-unit -propeller motifβ
I-like domain Cystein-rich
repeats
CD11
A Divalent cation sites
B C
 
Figure 3. Schematic structure of a CD11/CD18 integrin. A is the primary structure 
of CD11/CD18. B is the hypothetical model of the quaternary structure of 
CD11a/CD18. W = β-sheet. The I domain is inserted between W2 and W3 of the β-
propeller. The top of the I-like domain contacts W3 of the β-propeller (Adapted 
from Zang et al., 2000). C is the predicted combination of crystal structures of the I 
domain (top), with a central sheet of β-strands (thick ribbons) decorated 
peripherally by six α-helices (coiled ribbons), and the β-propeller  (bottom) 
containing seven four-stranded β-sheets arranged in a doughnut-like ring (Adapted 
from Chothia and Jones, 1997). For a better view, The I domain is artificially pulled 
out of the β-propeller domains 2 and 3. The regions known to be involved in ligand 
recognition in the I domain are indicated by *.  
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CD11a/CD18 mediates leukocyte adhesion to cells bearing any of five intercellular 
adhesion molecules (ICAM), which are either inducibly or constitutively expressed on nearly 
all cell types (Gahmberg, 1997). It may also bind to E-selectin (Kotovuori et al., 1993) and 
type I collagen (Garnotel et al., 1995). Thus, it participates in leukocyte recirculation, homing, 
and localization to inflammatory sites. 
CD11b/CD18 has a very broad binding capacity. It binds to ICAM-1, -2, and -4, iC3b, 
fibrinogen, serum factor X, heparin (Hemler, 1999), and platelet glycoprotein Ibα (Simon et 
al., 2000), E-selectin (Crutchfield et al., 2000), deoxyoligonucleotides (Benimetskaya et al., 
1997), elastase (Cai and Wright, 1996), high molecular weight kininogen (Sheng et al., 2000), 
β-glucan (Thornton et al., 1996), haptoglobin (El Ghmati et al., 1996), and other substances. 
 CD11c/CD18 binds to ICAM-1, iC3b, fibrinogen (Hemler, 1999), and type I collagen 
(Garnotel et al., 2000). The array of ligands recognized by CD11b/CD18 and CD11c/CD18 
facilitates myeloid cell adhesion to endothelium, transmigration, chemotaxis, phagocytosis of 
opsonized particles, degranulation, respiratory burst, and thrombus formation.  
CD11d/CD18 mediates binding to ICAM-3 and VCAM-1, and may contribute to 
trafficking of leukocyte subpopulations (Grayson et al., 1999) (Table 1).  
Although both CD11a/CD18 and CD11b/CD18 have been shown to bind to E-selectin, 
it is unknown whether these interactions are involved in leukocyte rolling. However, 
CD11a/CD18-ICAM-1-mediated leukocyte rolling on endothelium under physiological shear 
flow was recently reported (Sigal et al., 2000).  
 
“INSIDE-OUT” SIGNALING. Leukocyte adhesion is a dynamic process which needs 
to be tightly controlled in response to signals in the extracellular environment. Rapid, 
regulated modulation of ligand recognition is critical for leukocytes, since they must circulate 
in a non-adhesive state before targeting and arrest at specific sites. Leukocyte integrins play 
important roles in regulation of adhesion, by acting as bi-directional signal transducers, 
mediating signaling from inside-to-outside the cell (“inside-out”) and from outside-to-inside 
the cell (“outside-in”) (reviewed by Lub et al., 1995).   
β2 integrins are not constitutively active on resting leukocytes, but can be rapidly and 
transiently activated in response to cytoplasmic signals initiated by stimulation of other 
membrane receptors (“inside-out” signaling) such as T cell receptors and chemokine receptors 
(reviewed by Zell, 1999). Recent studies indicate that the signals can also come from cross-
talk of β2 integrins with other integrins (Chan et al, 2000; Imhof et al., 1997), ICAMs (Bleijs 
et al., 2000; Kotovuori et al., 1999), selectins (Ruchaud-Sparagano et al., 2000) and selectin 
ligands  (Evangelista et al., 1999), PECAM-1 (Piali et al., 1993), and other cell surface 
molecules (Petty et al., 1997; Porter and Hogg, 1998). The activation results in either an 
active comformation (high affinity state) or clustering (high avidity state) of integrins, both 
leading to strong ligand binding (Newton et al., 1997; reviewed by Zell et al, 1999).  
More than one pathway may mediate “inside-out” signaling of an individual ?2 
integrin. The most detailed analysis of “inside-out” signaling of ?2 integrins has been done 
for CD11a/CD18. Manipulation of the extracellular part of CD11a/CD18 using Mn
2+
, Mg
2+
, 
stimulating antibodies (Petruzzelli et al., 1995), or I domain peptides (McDowall et al., 1998) 
induces rapid dynamic changes in recognition of ICAM-1 and other ligands (high affinity). In 
contrast, treatment of T cells with phorbol ester (Kucik et al., 1996), or increased intracellular 
Ca
2+
 flux (van Kooyk et al., 1994) causes clustering of CD11a/CD18 and increased avidity of 
binding without detectable change in affinity (Kotovuori et al., 1999). Lateral motion of 
CD11a/CD18 in the plasma membrane is also enhanced by cytochalasins, or calpain, 
suggesting that the increased avidity state involves signals that alter cytoskeletal interactions 
(reviewed by Stewart et al., 1998; van Kooyk et al., 1999). Differential regulation of affinity 
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vs. avidity of CD11a/CD18 may involve a multi-step mechanism in which increased affinity 
and altered avidity occur in sequence (reviewed by Dustin, 1998). 
The cytoplasmic domains of CD11a/CD18 are important for “inside-out” signaling. 
Deletion of the GFFKR motif of CD11a causes constitutive ICAM-1 recognition, there is also 
additional evidence that the membrane-proximal region of the CD11a cytoplasmic tail exerts 
a general inhibitory effect on ligand recognition that is independent of the CD18 chain 
(Weber et al., 1999). The CD18 cytoplasmic tail is, however, critical for modulation of 
CD11a/CD18 adhesiveness (Hibbs et al., 1991). The CD18 chain associates with a variety of 
cytoskeletal and regulatory proteins, including ?-actinin, talin (Pardi et al., 1992; Sampath et 
al., 1998; Valmu et al., 1999a), filamin (Sharma et al., 1995; Valmu et al., 1999a), vinculin 
(Pardi et al., 1995; Pardi et al., 1992), cytohesin-1 (Geiger et al., 2000; Kolanus et al., 1996), 
and Rack1 (receptor for activated protein kinase C) (Liliental and Chang, 1998).  
The signal transduction pathways through which the “inside-out” signals are presented 
to leukocyte integrins remain poorly defined. Several studies propose mechanisms dependent 
on either the small GTPases, regulators of actin cytoskeleton assembly (reviewed by Tapon 
and Hall, 1997), which act downstream of protein kinase C (Jones et al., 1998; Laudanna et 
al., 1998; Laudanna et al., 1996), or phosphatidylinositol 3-kinase which, by recruiting 
cytohesin-1 to plasma membrane, converges signals with those from protein kinase C (Nagel 
et al., 1998; reviewed by Zell et al., 1999).   
   
“OUTSIDE-IN SIGNALING”. Engagement of integrins delivers “outside-in” signals 
that trigger intracellular transduction cascades, in addition to mediating adhesion. These 
“outside-in” signals can also be integrated with signals delivered through receptors for 
signaling molecules to yield coordinated functional responses. Cross-linking of leukocyte 
integrins with antibodies against the CD18 subunit, engagement of ?2 heterodimers with 
specific ligands, or coengagement of ?2 integrins together with other surface structures or 
receptors delivers “outside-in” signals that lead to diverse cellular responses (reviewed by 
Berton and Lowell, 1999). “Outside-in” signaling by specific ?2 integrins is impaired in 
leukocytes expressing I domain deleted CD11a/CD18 (Leitinger and Hogg, 2000), or from 
subjects with leukocyte adhesion deficiency type I (LAD I, see below) (Berton et al., 1994).  
Several intracellular signaling pathways are triggered by engagement of ?2 integrins, 
which mainly involve activation of protein tyrosine kinases and result in protein-protein 
interaction via SH2 domains (McGilvray et al., 1998; Petruzzelli et al., 1996; Rodriguez-
Fernandez et al., 1999). Activation of focal adhesion kinase (FAK) is central to many 
paradigms of “outside-in” signaling by integrins (reviewed by Cary and Guan, 1999). FAK 
binds peptides based on the sequence of the ?2 cytoplasmic domain in addition to ?1 and ?3 
cytoplasmic peptides (Schaller et al., 1995). Tyrosine phosphorylation of FAK occurs in 
leukocytes in response to ?2 integrin engagement (Rodriguez-Fernandez et al., 1999). 
Members of Src family kinases are also involved in ?2 induced signal transduction (Bohuslav 
et al., 1995), including Syk (Yan et al., 1997), Fgr, Hck (Lowell et al., 1996), and the related 
ZAP-70 (Soede et al., 1999).  
 
LEUKOCYTE ADHESION DEFICIENCY TYPE I (LAD I) AND LAD I VARIANT 
SYNDROMES. LAD I is a rare disease, with only approximately 200 patients reported. It 
results from heterogeneous mutations in the gene encoding the CD18 subunit. Humans with 
LAD I have absent or greatly reduced display of all ?2 integrin heterodimers on the surfaces 
of their leukocytes, absent or dramatically reduced accumulation of neutrophils and 
monocytes at extravascular sites, recurrent life-threatening bacterial infections, and impaired 
tissue remodeling and wound healing. Cells from these subjects have defective adhesive and 
signaling functions when studied in vitro (reviewed by Etzioni et al., 1999). Recently, variant 
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LAD I syndromes have been identified (Hogg et al., 1999; Kuijpers et al., 1997). Each of 
these subjects had clinical features consistent with LAD I, however, in contrast to the 
phenotype outlined above, they had normal or only moderately reduced levels of ?2 integrins 
(40- 60% of control) on the surfaces of circulating leukocytes at the time of diagnosis. In one 
subject, there were two new mutations in the CD18 chain, one was located in the MIDAS 
motif of the I-like domain (Hogg et al., 1999) resulting in expressed but nonfunctional ?2 
integrins. In the other two subjects, CD18 alleles are normal, but may have a defect in inside-
out signaling (Kuijpers et al., 1997). 
  
GENETICALLY-ALTERED ANIMAL MODELS. Mice with partial (Wilson et al., 
1993) and complete (Mizgerd et al., 1997; Scharffetter-Kochanek et al., 1998) deficiency of 
?2 integrins, and specific deletions of CD11a/CD18 (Andrew et al., 1998; Berlin-Rufenach et 
al., 1999; Schmits et al., 1996) and CD11b/CD18 (Coxon et al., 1996; Lu et al., 1997) have 
been produced (reviewed by Etzioni et al., 1999).  
Animals deficient in all ?2 integrins display phenotypic features of humans with LAD 
I, including neutrophilia (11-30 fold increase over wild-type), defect in accumulation of 
neutrophils into inflamed skin but not into inflamed peritoneum and lung, and compromised T 
cell function (Mizgerd et al., 1997; Scharffetter-Kochanek et al., 1998).  
CD11a knock-out mice show normal cytotoxic T cell responses to viruses but fail to 
reject immunogenic tumors (Schmits et al., 1996). Transendothelial migration of lymphocytes 
and neutrophils into inflamed peritoneum is also impaired (Andrew et al., 1998). In addition, 
CD11a/CD18 has a key role in migration of lymphocytes to peripheral lymph nodes, 
however, this can be compensated in knock-out mice by α4β1 and α4β7 integrins (Berlin-
Rufenach et al., 1999).  
Knock-out of CD11b has shown that CD11b/CD18 plays a critical role in neutrophil 
degranulation, iC3b-mediated phagocytosis, and binding to fibrinogen (Lu et al., 1997), 
however neutrophil accumulation into inflamed peritoneum is normal or even increased in the 
CD11b-deficient mice, a surprising result ascribed in part to impaired phagocytosis-induced 
neutrophil apoptosis (Coxon et al., 1996). The impairment of neutrophil effector functions in 
mice lacking CD11b/CD18 (Lu et al., 1997, Tang et al, 1997) may be potentially due to 
absent “outside-in” signaling or deficient signal integration. One of these studies indicated 
interaction between CD11b/CD18 and Fc receptors (Tang et al., 1997), which was predicted 
by earlier in vitro observations (Zhou and Brown, 1994). The same strain of mice was 
deficient in tissue mast cells, indicating that CD11b/CD18 is important in targeting and/or 
development of this extravascular leukocyte subtype (Rosenkranz et al., 1998). 
 
1.1.2. Immunoglobulin superfamily (IgSF) members 
 
The immunoglobulin superfamily (IgSF) comprises a large variety of glycoproteins 
(over 100) mostly expressed at the cell surface. Molecules carrying immunoglobulin (Ig) 
domains are endowed with broad functions including cytoskeletal organization, endocytosis, 
adhesion, migration, growth control, immune recognition, viral attachment, and tumor 
progression. The ever growing number of newly discovered Ig molecules has made this 
superfamily increasingly complex.  
Several members of the IgSF are found to mediate leukocyte adhesion. The most 
important molecules are the ICAMs, VCAM-1, MAdCAM-1, and PECAM-1. Other 
molecules which may contribute to adhesion include CD2, LFA-3 (CD58), activated 
leukocyte cell adhesion molecule (ALCAM, CD166), and L1. 
ICAMs are a subset of the IgSF that bind to leukocyte β2 integrins. There are now five 
members of this family (reviewed by Gahmberg et al., 1997a, b; Hayflick et al., 1998) (Fig. 
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4). ICAM-1 has a relatively broad distribution in different tissues, whereas ICAM-2, -3, -4, 
and -5 show more restricted patterns of tissue expression (Table 2). A more detailed 
description of this family is given in sections 2 and 4 of this review. 
VCAM-1, MAdCAM-1, and PECAM-1 (Table 2) have all been shown to mediate 
leukocyte adhesion to endothelium (Carlos and Harlan, 1994). VCAM-1 has six or seven 
(more abundant) extracellular Ig domains (Polte et al., 1991). It is expressed in endothelial 
cells and can be transcriptionally up-regulated by inflammatory stimuli. VCAM-1 binds to 
VLA-4 (Elices et al., 1990) and α4β7 (Ruegg et al., 1992), and is involved in leukocyte 
extravasation, production and maturation of B lymphocytes, and tumor metastasis. The first 
two domains of human VCAM-1, containing a VLA-4 binding site, have been crystallized 
(Jones et al., 1995), and in contrast to ICAM-1 and -2, the molecule has a more protruded 
loop in the first domain for integrin recognition. 
Human MAdCAM-1 has two extracellular Ig domains followed by a mucin-like 
domain. It is expressed predominantly on high endothelial venules of gut-associated lymphoid 
tissues. The first Ig domain supports binding to α4β7 (Berlin et al., 1993), while the mucin-
like domain binds to L-selectin (Berg et al., 1993), enabling MAdCAM-1 to participate in 
both initial L-selectin-dependent leukocyte tethering and rolling, and subsequent firm 
adhesion.  
 
 
Figure. 4. Schematic primary structures of ICAMs. The total or domain-specific 
sequence identities of ICAM-5 with the other ICAM members are shown in 
percentage. 
 
  19 
PECAM-1 (CD31) has six extracellular Ig domains. The cytoplasmic tail contains 
several serine and tyrosine residues that are phosphorylated after cell activation. (Newman, 
1997). It is constitutively expressed on endothelium, platelets, and leukocytes. PECAM-1 is 
involved in angiogenesis and leukocyte extravasation through homophilic adhesion (Fawcett 
et al., 1995), and heterophilic interaction with αVβ3 (Piali et al., 1995) and several other 
unidentified molecules (Piali et al., 1995). In addition, PECAM-1 may transduce intracellular 
signals that activate the integrins on leukocytes and platelets (Newman, 1997). 
Several other IgSF members are indicated in leukocyte adhesion as well (Elangbam et 
al., 1997) (Table 2). CD2 is a small protein of two Ig domains, it is expressed in T 
lymphocytes and acts as a costimulatory molecule for T cell activation by binding to its ligand 
LFA-3 expressed on diverse cell types (Davis et al., 1998). 
  
Members of IgSF in the immune System  
Members of IgSF 
 
MAJOR 
EXPRESSION 
THEIR LIGANDS 
ICAMs 
ICAM-1 (CD54) 
 
 
 
 
ICAM-2 (CD102) 
 
 
ICAM-3 (CD50) 
 
 
ICAM-4 (LW) 
 
ICAM-5 (telencephalin) 
 
 
Widely expressed: 
Leukocytes, 
Endothelial cells, 
Epithelial cells, 
Fibroblasts, etc. 
Endothelial cells, 
Leukocytes, 
Platelets 
Leukocytes 
 
 
Erythrocytes 
 
Neurons 
 
CD11a/CD18, 
CD11b/CD18, 
Fibrinogen, 
CD43, Hyaluronan, 
Rhinovirus, P. falciparum 
CD11a/CD18, 
CD11b/CD18 
 
CD11a/CD18, 
CD11d/CD18, 
DC-SIGN 
CD11a/CD18, 
CD11b/CD18 
CD11a/CD18, 
ICAM-5 
Others 
VCAM-1 (CD106) 
 
MAdCAM-1 
 
 
PECAM-1 (CD31) 
 
 
CD2 
LFA-3 (CD58) 
ALCAM (CD166) 
 
L1* 
 
 
Endothelial cells 
 
High endothelial venules 
(Peyer’s patches, mesenteric 
lymph nodes) 
Endothelial cells, 
Leukocytes, 
Platelets 
T lymphocytes 
Antigen-presenting cells 
Activated leukocytes, 
Thymic epithelial cells 
Neurons, 
Glia, 
Leukocytes 
 
VLA-4 (CD49d/CD29), 
α4β7 
α4β7, 
L-selectin 
 
αVβ3 (CD51/CD61), 
PECAM-1 
 
LFA-3 
CD2 
CD6 
 
α5β1, 
αVβ3 
 
Table 2. Members of IgSF in the immune system. The molecules, their major 
expression, and their ligands are listed. *: only the ligands of L1 that are involved in 
the immune function are listed here, while a large body of other L1-binding 
molecules are not shown. 
 
  20 
ALCAM has five Ig domains and is expressed by activated leukocytes and the thymic 
epithelial cells. It is implicated in the regulation of T cell adhesion and activation by binding 
to CD6, a member of the scavenger receptor family (Bajorath et al., 1995). 
The cell-adhesion molecule L1 was originally described in the nervous system, but has 
recently been detected in leukocytes in the immune system (Pancook et al., 1997). It has six 
extracellular Ig domains followed by five FnIII-like domains. In the nervous system, it is 
mainly involved in neuronal adhesion, neurite fasciculation, and stimulation of the fibroblast 
growth factor (FGF)-receptor-dependent neurite outgrowth by homophilic interaction 
(Kenwrick et al., 2000). In the immune system, L1 supports lymphocyte migration and 
aggregation through its binding to the "classical" vitronectin receptor αVβ3 (Montgomery et 
al., 1996), and fibronectin receptor α5β1 (Ruppert et al., 1995), respectively (reviewed by 
Kadmon et al., 1998). In addition, recent observation on L1-deficient mice reveals that L1 is 
involved in the marginal sinus integrity of the splenic white pulp (Wang, et al. 2000). 
 
1.1.3. Selectins 
 
Selectins are a family of cell-cell adhesion proteins which are involved in the dynamic 
interactions of leukocytes with the vascular endothelium (Vestweber and Blanks, 1999). The 
selectins consist of three members, which have various names. L-selectin (LECAM-1, 
CD62L) is the leukocyte selectin, E-selectin (ELAM-1, CD62E) and P-selectin (GMP-140, 
CD62P) are the endothelial selectins. P-selectin is also expressed in platelets. They are type I 
transmembrane proteins composed of an amino terminal calcium-type lectin domain, an 
endothelial growth factor motif, a series of contiguous (2-9) short consensus repeats, a single-
pass transmembrane domain, and a short cytosolic tail.   
 In contrast to the integrins and members of the IgSF (exclusive of the sialoadhesins), 
whose functions rely on protein-protein interactions, the selectins mediate adhesion through 
recognition of specific carbohydrate determinants presented on glycoproteins, glycolipids, 
and proteoglycans (reviewed by Varki, 1997). The carbohydrate determinants are sialyl Lewis 
X (SLe
x
) and related structures, which bind to the lectin domains of selectins. L-selectin 
recognizes MAdCAM-1 (Berg et al., 1993), CD34, and glycosylation-dependent cell adhesion 
molecule (GlyCAM)-1 (Varki, 1997), which are mucin-like proteins expressed on 
endothelium. Both P- and E-selectins bind to the P-selectin glycoprotein ligand (PSGL)-1, 
and E-selectin also recognizes the E-selectin ligand (ESL)-1 (Varki, 1997), which are both 
expressed in leukocytes. Some other glycoproteins have been included as selectin ligands as 
well. Among them are complement factor H (Malhotra et al., 1999) which binds to L-selectin, 
CD24 (Sammar et al., 1994) which binds to P-selectin, β2 integrins (Crutchfield et al, 2000; 
Kotovuori et al., 1993) and cutaneous lymphocyte antigen (CLA) (Berg et al., 1991) which 
bind E-selectin. Besides, L-selectin was also reported to present carbohydrate ligands to the 
vascular P- and E-selectins (Picker et al., 1991). 
Selectins are specialized in capturing leukocytes from the bloodstream to the blood 
vessel wall. This initial cell contact is followed by the selectin-mediated rolling of leukocytes 
on the endothelial cell surface. This represents the first step in a cascade of molecular 
interactions that lead to leukocyte extravasation, enabling the processes of lymphocyte 
recirculation and leukocyte migration into inflamed tissue. The central importance of the 
selectins in these processes has been well documented in vivo by the use of adhesion-blocking 
antibodies as well as by studies on selectin gene-deficient mice (Frenette and Wagner, 1997) 
and patients with leukocyte adhesion deficiency type II, a disease of deficient cell surface 
expression of SLe
x
 epitope recognized by selectins (Becker and Lowe, 1999). Recently, a 
child with severe recurrent infections and low expression of E-selectin on blood vessel 
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endothelium caused by increased cleavage of E-selectin was reported. This could be a third 
LAD syndrome (DeLisser et al., 1999).  
A novel and exciting aspect is the signaling function of the selectins and their ligands. 
Especially in the past two years, convincing data have been published supporting the idea that 
selectins and their glycoprotein ligands participate in the activation of leukocyte integrins 
(Crockett-Torabi, 1998). 
 
1.1.4. Sialomucins 
 
There are two types of cellular mucins which have thus far been described separately 
in the literature: epithelium-associated and endothelium/blood cell-associated mucins (Van 
Klinken et al., 1995). Recently, endothelial and leukocyte-associated mucins have been 
proposed to represent a new class of adhesion molecules and have been termed the sialomucin 
adhesion family (Dianzani and Malavasi, 1995). This family includes CD34, PSGL-1, CD43, 
PCLP, CD45RA, CD164, as well as GlyCAM-1 and MAdCAM-1(Verfaillie, 1998), most of 
which are selectin ligands.  
Mucins in general contain several threonine and serine residues, which are extensively 
O-glycosylated. Due to this profound glycosylation, mucins may have a filamentous 
conformation. By virtue of their extended filamentous, and often negatively charged structure, 
mucins like CD43 can act as an anti-adhesive barrier protecting the cell (Seveau et al., 2000). 
However, when an opposing cell has specific receptors for mucins, such as selectins reviewed 
in section 1.1.3., adhesion can override the barrier function. 
 
1.1.5. Other adhesion molecules 
 
Although the primary adhesion of lymphocytes to endothelium has been primarily 
attributed to the selectin family of receptors, CD44 can also mediate this function when 
activated to bind its ligand hyaluronan, a component of the ECM (Bennett et al., 1995). 
Triggering through the T cell receptor induces activated CD44 and CD44-dependent primary 
adhesion in both human and mouse lymphocytes, and the interaction can mediate the 
extravasation of activated T cells into an inflamed site (reviewed by Johnson et al., 2000). 
Vascular adhesion protein-1 (VAP-1) (Jalkanen and Salmi, 1993) and lymphocyte-
vascular adhesion protein-2 (LVAP-2) (Airas et al., 1993) are novel contact-initiating 
molecules for lymphocyte binding to high endothelial venules, although their 
counterreceptors on lymphocytes are currently unknown. Thus, they seem to be involved in 
lymphocyte homing independent of the L-selectin pathway as well  (Butcher and Picker, 
1996). 
Fractalkine, a novel CX3C chemokine, is found on activated endothelial cells in a 
membrane-bound form, in addition to the soluble isoform (Bazan et al., 1997). It has an 
amino terminal globular CX3C domain followed by a stalk of a mucin-like domain in the 
extracellular portion. Through its CX3C domain binding to an “orphan” receptor CX3CR1 
expressed on natural killer cells and monocytes, it functions as an adhesion molecule to 
capture and induce firm adhesion of a subset of leukocytes in a selectin- and integrin-
independent manner (Goda et al., 2000).  
It should not be assumed that the adhesion molecule pairs discussed above are the 
only, or even universally predominant, molecular participants in leukocyte- endothelial 
interactions. As new adhesion molecules are coming into light, there are still novel leukocyte–
endothelium adhesion pathways left to be defined. 
 
1.2. Leukocyte recruitment to the central nervous system (CNS) 
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The recruitment of circulating leukocytes into inflammatory lesions requires adhesion 
to vascular endothelium, followed by transendothelial migration into the underlying tissues. 
The recruitment of leukocytes into the CNS is complicated by the existence of a specialized 
microvasculature, characterized by the presence of a continuous network of complex tight 
junctions, stringent molecular transport systems and specific enzymes. Under the control of 
surrounding astrocytes, this microvasculature constitutes the blood-brain-barrier (BBB) that 
limits the exchange between blood and brain of soluble substances such as hormones, growth 
factors, cytokines, or immunoglobulins (reviewed by Pardridge, 1999). On the basis of the 
existence of the BBB, and the very low levels of major histocompatibility complex (MHC) 
molecules on brain cells, the CNS has often been considered as an “immunologically 
privileged” organ, not normally accessible to leukocyte traffic. Hence, knowledge of the 
interactions between inflammatory cells and the CNS cells is quite limited as compared to that 
of other tissues or organs. 
Nevertheless, haematopoietic cells can and do enter the CNS in a number of 
circumstances. Derivatives of the monocyte/macrophage lineage appear to enter and take up 
residence in various structures of the CNS as part of normal ontogeny and physiology. 
Activated lymphocytes can cross into the CNS at a very low level under normal conditions 
and in much higher numbers during neurological autoimmune disorders like multiple sclerosis  
 
  
Figure 5. Transendothelial migration of T lymphocytes through the 
BBB. (Adapted from Lee and Benveniste, 1999). Abbreviations: Ast, 
astrocyte; BBB, blood–brain barrier; E, endothelial cell; Mi, microglia; 
T, T lymphocyte; TCR, T-cell receptor. 
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(MS). Also, virus spreading into the brain has been suggested, in the case of human 
immunodeficiency virus (HIV), to be initiated by infiltration of infected monocytes through 
the BBB. 
The present review will focus on recent progress in the field, and will highlight the 
multidirectional communication network based on adhesion molecules, which involves 
interactions between infiltrating leukocytes, brain microvessel endothelial cells, glial cells 
including astrocytes, oligodendrocytes, microglia, and neurons (Fig. 5).  
 
1.2.1. Interactions between leukocytes and brain endothelial cells 
 
It was for many years thought that leukocyte traffic in the CNS was minimal or non-
existing. However, it has become evident that leukocytes of all types can enter the CNS 
(reviewed by Hickey, 1999). Five basic groups of leukocytes, T lymphocytes, B lymphocytes, 
natural killer cells, neutrophils, and monocyte/macrophages, all appear in the CNS either in 
the normal state or during various diseases. T lymphocytes play vital roles in autoimmune 
diseases such as MS (reviewed by Bar-Or et al., 1999), and viral encephalitis (reviewed by 
Roos, 1999). B lymphocytes (reviewed by Archelos et al., 2000) and natural killers (reviewed 
by Lenz and Swanborg, 1999) both appear in MS although their functions are still unclear. 
Neutrophils are the first cells to appear in cerebral ischemia and trauma (Feuerstein et al., 
1998). Monocytes/macrophages usually infiltrate at the later stage of inflammatory reactions 
in the CNS, with the exception of HIV encephalitis, which is characterized by large numbers 
of infiltrating monocyte-derived macrophages at the beginning of the disease (Nottet, 1999). 
Most research on cellular entry into the CNS from the circulation has been focused on 
understanding the mechanisms of T lymphocyte mediated inflammation. In 1991, Hickey et al 
demonstrated that activated, but not naïve, T lymphocytes can enter the CNS to perform 
immune surveillance under normal conditions (Hickey et al., 1991). The phenotype of 
infiltrated T lymphocytes has been characterized by several studies. CNS T lymphocytes are 
phenotypically unique compared to those of other inflamed tissues. T lymphocytes from 
inflamed CNS are mainly CD4
+
 and are the only population examined that express a typical 
activated/memory phenotype: high levels of CD44, CD11a/CD18 and ICAM-1, and low 
levels of CD45RB. The CNS T lymphocytes lack α6 and αE integrin chains, but express 
α4β7 integrin and high levels of activated VLA-4 integrin. In contrast, most T lymphocytes in 
the gut express low levels of activated β1 integrin. In addition, in contrast to the L-selectinhigh 
phenotype of naïve T lymphocytes, infiltrating CNS lymphocytes lack L-selectin. However, 
in inflamed CNS, approximately 50% of T lymphocytes express high affinity ligands for P-
selectin while fewer than 10% express high affinity ligands for E-selectin (Engelhardt et al., 
1998).  
T lymphocytes incapable of inducing diseases in the animal enter the nervous system 
with the same kinetics as those which would result in inflammatory disease. Thus the 
activated T lymphocytes which enter the CNS depend on their activation state. However, 
there is a critical distinction between the trafficking pattern of lymphocyte subsets which 
could produce disease and those which cannot. Encephalitogenic lymphocytes (those which 
would find their antigen in the CNS parenchyma) appear to arrest there, while those which 
could not recognize antigens in the CNS, either because they were not specific for a neural 
tissue antigen, or because they could not recognize the antigen in the context of the host’s 
MHC molecules, disappear (Hickey et al., 1991). 
 It is obvious that all activated T cells in the circulation do not go only to the CNS, but 
they seem to enter all the tissues of the body in a relatively random manner. However, the 
concentration of T lymphocytes in tissues is not evenly distributed among different organs. 
The T lymphocyte concentration in the CNS is relatively lower than in the other organs. Also, 
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there seems to be differences in the amount of T lymphocytes in different regions of the CNS 
(Yeager et al., 2000). Whether this is due to the different levels of adhesion molecules 
expressed in the CNS or some undefined parenchymal factor is unclear; however some data 
do suggest that under normal conditions, adhesion molecules such as VCAM-1 and ICAM-1 
are expressed at much lower levels in brain endothelial cells than in the other types of 
endothelial cells (dos Santos et al., 1996: Stins et al., 1997). 
 A central question concerning the passage of activated T lymphocytes into the CNS 
relates to the molecular nature of the interactions between T lymphocytes and CNS 
endothelial cells in health and disease. A body of literature suggests that CNS endothelial 
cells, strategically located at the interface between blood and brain, are actively involved in 
the process of leukocyte infiltration into the brain. In vitro studies of cultured cerebral 
endothelial cells have demonstrated the exceptionally low and no expression of ICAM-1 and 
VCAM-1 in unstimulated brain endothelium, respectively (dos Santos et al., 1996; Stins et al., 
1997); however, their expression can be markedly enhanced by treatment of brain endothelial 
cells with a number of inflammatory mediators such as tumor necrosis factor (TNF)α, 
interferon (IFN)γ, interleukin (IL)-1β, and lipopolysaccharide (LPS) (Wong and Dorovini-Zis, 
1992). In addition, the contact between T lymphocytes and CNS endothelium causes 
increased adhesion molecule expression and cytokine production by the endothelium (Lou et  
 
 Adhesion molecules involved in immune-CNS interaction 
 
ADHESION 
MOLECULES 
 
 
MAJOR EXPRESSION 
Integrins 
CD11a/CD18 (LFA-1) 
CD11b/CD18 (Mac-1) 
VLA-1 (CD49a/CD29) 
VLA-2 (CD49b/CD29) 
VLA-3 (CD49c/CD29)  
VLA-4 (CD49d/CD29) 
VLA-5 (CD49e/CD29) 
VLA-6 (CD49f/CD29) 
αVβ1 (CD51/CD29) 
αVβ3 (CD51/CD61) 
αVβ5 
 
Microglia, infiltrating leukocytes 
Microglia, infiltrating leukocytes 
Astrocytes, oligodendrocytes, brain endothelial cells 
Astrocytes, oligodendrocytes  
Astrocytes, brain endothelial cells 
Microglia, infiltrating leukocytes 
Astrocytes 
Astrocytes, oligodendrocytes, brain endothelial cells 
Oligodendrocytes 
Brain endothelial cells, oligodendrocytes 
Oligodendrocytes 
IgSF members 
ICAM-1 (CD54) 
 
ICAM-5 
VCAM-1 (CD106) 
LFA-3 (CD58) 
PECAM-1 (CD31) 
 
Brain endothelial cells, astrocytes, microglia, 
oligodendrocytes, neurons* 
Neurons 
Brain endothelial cells, astrocytes, microglia, neurons* 
Brain endothelial cells, astrocytes, microglia 
Brain endothelial cells,  
Selectins 
P-selectin 
E-selectin 
 
Brain endothelial cells 
Brain endothelial cells, astrocytes* 
Table 3. The major cellular expression of adhesion molecules involved in the 
immune-CNS interaction are listed. *: Found to express only after cytokine 
stimulation on these cells.  
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al., 1996). Also, constitutive expression of P- and E-selectins on CNS endothelium is very 
low or absent, but can be induced by cytokine stimulation (Engelhardt et al., 1997). In vivo 
studies of MS have also shown the increased expression of ICAM-1, VCAM-1, and E-selectin 
in brain endothelium of MS lesions (Cannella and Rainne, 1995) (Table 3). 
Taken together, these observations suggest the involvement of integrins and their 
ligands in the CNS recruitment of lymphocytes (reviewed by Archelos et al., 1999). In 
agreement, the involvement of VLA-4/VCAM-1 interaction in lymphocyte entry into the CNS 
of animals has been shown. Therapy with a monoclonal antibody against VLA-4 diminished 
the infiltration of VLA-4-positive cells into the brain, and suppressed experimental 
autoimmune encephalomyelitis (EAE), an animal model of MS (Yednock et al., 1992). Also, 
VLA-4 deficient antigen-specific T lymphocytes fail to cross the BBB (Baron et al., 1993). In 
a similar manner, utilization of the CD11a/CD18/ICAM-1 pathway in lymphocyte 
recruitment of EAE models is also demonstrated by antibody blocking tests (Greenwood et 
al., 1995; Male et al., 1994). In contrast, the role of α4β7/VCAM-1 interaction in CNS 
recruitment of lymphocytes is still controversial (Engelhardt et al., 1998; Kanwar et al-, 
2000). Likewise, selectins also play obscure roles, recent data suggest that P- and E-selectins 
play little, if any, role in T lymphocyte recruitment into the CNS in the pathogenetic process 
of EAE (Engelhardt et al., 1997). But P-selectin may participate in attachment of activated T 
lymphocytes to normal, non-inflamed CNS endothelium (immune surveillance) (Carrithers et 
al., 2000).    
Integrins are well known for their functions as signal transducers (Coppolino and 
Dedhar, 2000). More recently, accumulating data demonstrate that cell adhesion molecules of 
the IgSF can transmit signals in an “outside-in” fashion as well. Most of these studies have 
utilized monoclonal antibodies to cross-link surface adhesion molecules. Among the CNS 
adhesion molecules, ICAM-1 has been most extensively studied. In brain endothelial cells, 
ICAM-1 cross-linking induced tyrosine phosphorylation of the cytoskeletal-associated protein 
cortactin, suggesting that signaling through ICAM-1 may affect cytoskeletal reorganization of 
endothelial cells, which may facilitate extravasation of leukocytes through the BBB (Durieu-
Trautmann et al., 1994). A recent study has demonstrated that ICAM-1 signaling in brain 
endothelial cells is associated with Rho activation, and subsequent tyrosine phosphorylation 
of the cytoplasmic proteins focal adhesion kinase, paxillin, and p130cas. This supports the 
notion of ICAM-1 mediated changes in cell shape (Etienne et al., 1998). In a follow-up study, 
it was shown that ICAM-1 cross-linking of brain endothelial cells resulted in reorganization 
of the endothelial actin cytoskeleton, and this event was critical for migration of lymphocytes 
through endothelial cell monolayers (Adamson et al., 1999). These findings indicate that brain 
endothelial cells are actively involved in facilitating T lymphocyte migration, and that this 
process requires ICAM-1 mediated rearrangement of the endothelial actin cytoskeleton, as 
well as activation of Rho proteins. In addition, these findings have implications for T 
lymphocyte activation of endothelial cells (through CD11a/CD18/ICAM-1 interactions) being 
intimately involved in facilitating lymphocyte migration across the BBB. 
Some additional adhesion molecules are also found on brain endothelium, but their 
functions in the CNS have not been much studied (Table 3). Integrins VLA-1, -3, and -6, as 
well as αvβ3 are found on endothelial cells in MS lesions. VLA-6 is distributed throughout 
endothelial cells, whereas αv and VLA-1 are on intercellular junctions (Sobel et al., 1998). 
Besides, PECAM-1 (Wong et al., 1999), LFA-3 and CD44 have been found on normal brain 
endothelium  (Rossler et al., 1992). 
 
1.2.2. Interactions between leukocytes and glial cells 
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It is noteworthy that CNS resident glial cells (astrocytes, oligodendrocytes, and 
microglia) are also found to express adhesion molecules (reviewed by Lee and Benveniste, 
1999) (Table 3). Astrocytes, the most abundant glial cells of the CNS, constitutively express 
ICAM-1 and VCAM-1, and their expression is enhanced by cytokines (Rosenman et al., 
1995; Shrikant et al., 1994). In Alzheimer’s (AD) and acute MS lesions, astrocytes are 
positive for ICAM-1 immunostaining (Akiyama et al, 1993; Brosnan et al., 1995). Recently, it 
was found that crosslinking of ICAM-1 on astrocytes induces TNF-α secretion together with 
phosphorylation of the transcription factor cAMP response element-binding protein (CREB). 
ICAM-1 crosslinking also induces cAMP accumulation and activation of the mitogen-
activated protein kinase extracellular signal-regulated kinase. Both pathways are responsible 
for CREB phosphorylation and TNF-α secretion. Moreover, these responses are partially 
dependent on protein kinase C, which acts indirectly, as a common activator of cAMP/protein 
kinase A and extracellular signal-regulated kinase pathways (Etienne-Manneville et al., 1999). 
These results constitute the first evidence of ICAM-1 coupling to intracellular signaling 
pathways in glial cells and demonstrate the convergence of these pathways onto transcription 
factor regulation and TNF-α secretion. It indicates that ICAM-1-dependent cellular adhesion 
to astrocytes could contribute to the inflammatory processes observed during leukocyte 
infiltration in the CNS. Astrocytes also express VLA-1, -2, -5, and -6 integrins which are 
cellular receptors for ECM components. Among these molecules, VLA-1, -2, and -6, but not 
VLA-5, are upregulated by cytokines (Aloisi et al., 1992). The regulation of cell surface ECM 
receptor expression implies that cytokines may influence astrocyte function by altering their 
adhesion to the ECM during the course of CNS inflammation.    
Oligodendrocytes, which are cells mediating axonal myelination in the CNS, 
constitutively express ICAM-1 and its expression is upregulated by cytokines (Satoh et al., 
1991). The myelin sheath surrounding the neuronal axons contains a ligand for L-selectin, and 
has been shown to mediate adhesion of L-selectin bearing lymphocytes  to myelinated axons 
(Huang et al., 1994). In addition, integrins VLA-1, VLA–6, αvβ1, αvβ3, and αvβ5 were 
found on oligodendrocytes under normal conditions (Milner, 1997); and VLA-2 was observed 
on oligodendrocytes in active lesions of EAE (Previtali et al., 1997) (Table 3). It is suggested 
that oligodendrocyte migration can be regulated by altering integrin expression, which would 
support a future therapeutic strategy for repair of widespread demyelinated lesions (Milner, 
1997).  
Microglia are the resident macrophages of the CNS (reviewed by Stoll and Jander, 
1999). In resting (ramified) state, microglia constitutively express ICAM-1 and its expression 
is upregulated by certain cytokines (Shrikant et al., 1995). They also express high levels of the 
CD11a/CD18 and CD11b/CD18 integrins, and very low level of VLA-4 integrin (Dalmau et 
al., 1997; Hailer et al., 1996). However, in the activated (amoeboid) state, microglial 
expression of VLA-4 is greatly enchanced (Hailer et al., 1996). It is generally accepted that 
microglia derive from monocytes that infiltrate into the CNS during development, and several 
studies demonstrate that interactions between β2 integrins and their ligands underlie the 
mechanism for the recruitment of microglial precursors (Dalmau et al., 1997; Rezaie et al., 
1997).  Under pathological conditions, CD11a/CD18 immunostaining is positive on activated 
microglia located close to the edge of demyelinating lesions (Bo et al., 1996) or senile plaques 
of Alzheimer’s disease (AD) (Akiyama et al., 1993). In addition to its interaction with 
infiltrated leukocytes, microglia themselves play important roles as major immune effector 
cells in several neurological disorders such as HIV encephalopathy, MS, and AD (reviewed 
by Gonzalez-Scarano and Baltuch, 1999) (Table 3).  
Thus far, the physiological role of adhesion molecule expression on glial cells has not 
been well characterized. However, based on the general role of adhesion molecules in other 
cell types, two possible roles can be inferred: (1) a role in leukocyte recruitment: Since 
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astrocytes are a structural component of the BBB, it is quite conceivable that ICAM-1 and 
VCAM-1 expressed on activated astrocytes facilitate the transendothelial migration of 
leukocytes into CNS parenchyma, which is initiated by adhesion molecule expression on 
brain endothelial cells. (2) a role in antigen presentation (reviewed by Lee and Benveniste, 
1999): During the pathogenesis of EAE, encephalitogenic T lymphocytes require two steps 
for the activation process. Upon antigen challenge, encephalitogenic T lymphocytes are 
activated by professional antigen presenting cells (APCs) in peripheral lymphoid organs and 
transmigrate through the BBB. After the primary activation, T lymphocytes need to be 
activated again in the CNS by local APCs to exert their effector functions. There is 
controversy regarding which cell types actually function as APCs in the CNS. Much of the 
literature suggests that microglia are the most efficient APCs within the brain parenchyma 
(Aloisi et al., 1998; Shrikant and Benveniste, 1996), although there is a debate that microglial 
cells isolated from adult brain show the phenotype of immature APCs and fail to function as 
efficiently as APCs (Carson et al., 1998). In addition, there are reports that activated 
astrocytes are capable of presenting antigen to encephalitogenic T cells (Soos et al., 1998). 
Even though the antigen presenting capacity of microglia or astrocytes in the CNS needs to be 
further clarified, it is quite possible that adhesion molecules expressed on glial cells can 
modulate T lymphocyte activation by increasing the adhesiveness of cell-cell interactions 
and/or by delivering costimulatory signals through their receptors on T lymphocytes. 
 
1.2.3. Interactions between leukocytes and neurons 
 
During inflammatory diseases of the CNS, some adhesion molecules are also 
expressed in neuronal cells, which might mediate direct interaction between infiltrated 
leukocytes and neurons. ICAM-1 and VCAM-1 expression in human neurons in response to 
cytokines in vitro has been documented by several studies (Birdsall et al., 1992; Hery et al., 
1995; White et al., 1994). These adhesion molecules mediate the neuronal binding of 
cytotoxic T lymphocytes (White et al., 1994), monocytes (Hery et al., 1995) or neutrophils 
(Birdsall et al., 1992). Binding of leukocytes to neurons may induce the subsequent release of 
neurotoxic radicals into the cytoplasm of neurons and result in neuronal injury (Birdsall, 
1991). Neurotoxicity associated with HIV infection has also been demonstrated to be, at least 
partialy, mediated by cell-cell interaction between HIV-infected monocytes and neurons 
(Tardieu et al., 1992). In addition, ICAM-5 (telencephalin), a novel cell adhesion molecule, 
was found to be constitutively expressed on cerebral neurons (Yoshihara et al., 1994), and its 
interaction with LFA-1 induces rapid cell spreading of microglia and clustering of 
CD11a/CD18 on the microglial surface membrane (Mizuno et al., 1999) (Table 3). 
A variety of other adhesion molecules are also found on neurons, such as NCAM, L1, 
and related adhesion molecules, as well as integrins. Since they are more important in 
neuronal differentiation and synaptic plasticity, they will be separately dealt with in section 3 
of this review. 
In conclusion, a multidirectional communication network probably exists in brain 
between leukocytes and CNS cells, especially during neuropathological disorders. Whereas 
under normal conditions, the level of leukocyte adhesion to brain endothelium is too low to 
initiate the leukocyte migration across the BBB, with the exception of a few activated T 
lymphocytes, which induce the enhanced expression of adhesion molecules on CNS 
endothelial cells through a number of inflammatory cytokines. They may cross the BBB in an 
antigen-independent way. Astrocytes and microglia, under pathological conditions, further 
induce leukocyte extravasation into the CNS parenchyma, and amplify the inflammatory 
process by presenting brain antigens to infiltrated lymphocytes, and inducing secretion of 
cytokines and chemokines. Demyelination and /or neurotoxicity may follow, caused by either 
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cytokines or cell-cell contacts between activated leukocytes and oligodendrocytes or neurons 
(Fig. 5). 
 
2. INTERCELLULAR ADHESION MOLECULES (ICAM) 1-4 
  
2.1. ICAM-1 (CD54) 
 
2.1.1. Structure and binding partners 
 
ICAM-1 is a type I transmembrane glycoprotein of 85~110 kDa with a polypeptide of 
55 kDa composed of five tandem Ig domains, a transmembrane domain, and a short 
cytoplasmic tail (Patarroyo et al., 1987; Staunton et al., 1988) (Fig. 4). The ~100-amino acid 
Ig domain is formed by a tightly packed barrel of antiparallel β strands arranged in two layers 
that are held together by disulfide bridges (Chothia and Jones, 1997). ICAM-1 is heavily 
glycosylated, with eight N-linked glycans, but none on the first domain. In addition to its 
membrane-bound form, soluble ICAM-1 containing five Ig domains also exists in human 
serum due to proteolytic cleavage (Rothlein et al, 1991). Besides, alternatively spliced forms 
of both membranous and soluble ICAM-1 that contain domain 1, but lack domains 2, 3, and 4 
in different combinations, are found in mice (King et al., 1995; van Den Engel et al, 2000). 
Both membranous and soluble ICAM-1 have been reported to form dimers (Miller et al, 1995; 
Reilly et al., 1995). The crystal structure of domains 1 and 2 of human ICAM-1 shows that 
ICAM-1 dimerizes over a hydrophobic interface on the BED sheet of domain 1, in agreement 
with dimerization of ICAM-1 on the cell surface (Casasnovas et al., 1998) (Fig. 6B). 
ICAM-1 is a ligand for leukocyte integrins CD11a/CD18 and CD11b/CD18 (Table 2). 
Through their I domains in the α chains, CD11a/CD18 and CD11b/CD18 bind to domain 1 
(Staunton et al., 1990) and domain 3 (Diamond et al., 1991) of ICAM-1, respectively. 
Site-directed mutagenesis on ICAM-1 indicates that an acidic residue, glutamate at 
position 34 of domain 1, is the most important residue for CD11a/CD18 binding (Staunton et 
al., 1990). Crystal structures of ICAM-1 reveal that the residues bound by CD11a/CD18 are 
well oriented for bivalent binding in ICAM-1 dimer, with the critical glutamate
34 
residues 
pointing away from each other on the periphery. The interaction of ICAM-1 with 
CD11a/CD18 is mediated by a divalent cation bound to the I domain of CD11a/CD18 and the 
carboxyl group of the glutamate
34
 residue on ICAM-1 (Bella et al., 1998; Casasnovas et al., 
1998) (Fig 6A and B). In fact, together with the so far determined crystal structures of other 
adhesion molecules such as ICAM-2, VCAM-1, and MAdCAM-1, it is generally accepted 
that an acidic residue near the bottom of domain 1 plays a key role in integrin binding. For 
ICAM-1 and ICAM-2, this acidic residue is glutamate, and is located on a flat surface, 
complementary to the flat surface of the I domain of CD11a/CD18. For VCAM-1 and 
MAdCAM-1, the acidic residue is aspartate, and it resides on a protruded CD loop which may 
be complementary to a more pocket-like structure in the α4 integrins which lack I domains 
(reviewed by Wang and Springer, 1998). 
Rotary shadowing electron microscopy indicates that there is a bend between domains 
3 and 4 (Staunton et al., 1990). ICAM-1 has been proposed to protrude on cell surface as a 
bended dimer, which presents the integrin-binding surface toward the opposing cell for 
adhesion, and prevents cis interaction with integrins on the same cell (Wang and Springer, 
1998).     
ICAM-1 is also a receptor for pathogens such as the major group of rhinovirus 
(Staunton et al., 1990) and Plasmodium falciparum (Berendt et al., 1992) (Table 2). The 
binding sites for CD11a/CD18, rhinovirus, and Plasmodium falciparum are overlapping, but 
non-identical in domain 1 of ICAM-1. Crystal structures show that residues binding to 
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rhinovirus are in the flexible BC and FG loops at the tip of domain 1. The loops are 
considerably different in structure to those of human ICAM-2 or murine ICAM-1, which do 
not bind rhinoviruses (Bella et al., 1998; Casasnovas et al., 1998), and these and the upper 
half of domain 1 are well exposed in the ICAM-1 dimer for docking to virus. By contrast, a 
residue important for binding to Plasmodium falciparum-infected erythrocytes is in the 
ICAM-1 dimer interface (Casasnovas et al., 1998).  
   
1
2
3
4
5
1
2
3
4
5
E34 E34A B
ICAM-1
1
2
E37
C D
ICAM-2
 
Figure 6. CD11a/CD18-binding surfaces of ICAM-1 and ICAM-2. Stereoviews of 
the crystal structures of domain 1 of ICAM-1 (A) and ICAM-2 (C) are shown 
(Adapted from Casasnovas et al., 1999). The backbone is shown in grey as a ribbon 
diagram with β-strands lettered. Disulfide bonds are shown in grey. Side chains of 
individual residue tested by mutagenesis are shown as ball and stick. The carbons 
and bonds of these side chains are color-coded according to the percentage of wild-
type binding to CD11a/CD18 after mutagenesis: red, <35%; yellow-orange, 35-
70%; green, >70%; magenta, <35% with a possible effect on domain structure. Side 
chain oxygen and nitrogen atoms are yellow and blue, respectively. B and D are the 
schematic models of membrane-bound ICAM-1 and ICAM-2, respectively. The 
tripod-like N-linked glycans in domain 2 of ICAM-2 are shown in blue (D). 
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ICAM-1 has also been found to bind to the γ chain of fibrinogen through its first Ig 
domain (D'Souza et al., 1996). In addition, CD43 (Rosenstein et al., 1991), and hyaluronan 
(McCourt et al., 1994) are reported to bind ICAM-1, but their binding sites in ICAM-1 have 
not been mapped yet (Table 2).  
 
2.1.2. Expression 
 
ICAM-1 has a broad tissue distribution, it is expressed on a variety of both 
haematopoietic and non-haematopoietic lineages including leukocytes, endothelial cells, 
epithelial cells, and fibroblasts etc. However, its basal expression level is low, but can be 
upregulated by a number of inflammatory mediators such as IL-1, TNFα, IFNγ, and LPS. 
Therefore, ICAM-1 is normally restricted in expression, but becomes more abundant in 
tissues undergoing immune or inflammatory reactions (reviewed by Hubbard and Rothlein, 
2000).  
ICAM-1 expression is mainly transcriptionally regulated. The ICAM-1 promoter 
contains several enhancer elements including STAT1 element for IFNγ signaling, and NF-κB 
and c-Rel elements for TNFα, IL-1, LPS, or glucocorticoids signalling. Regulation of ICAM-
1 expression is cell specific and depends on the availability of cytokine receptors, signal 
transduction pathways, transcription factors, and post-transcriptional modification (Hubbard 
and Rothlein, 2000).  
 
2.1.3. Cytoplasmic association 
 
In contrast to integrins, the cytoplasmic domains of ICAMs are poorly conserved 
(reviewed by Hayflick et al., 1998). This might reflect the different functions of their 
cytoplasmic domains. ICAM-1 has a short cytoplasmic tail with only 28 amino acids. ICAM-
1 lacks the motifs resembling the Src homology domains that can recruit phosphorylated 
proteins at the cytoplasmic, membrane-proximal site. Nevertheless, recent data indicates that 
upon fibrinogen ligation, ICAM-1 can be tyrosine phosphorylated and the phosphorylation 
results in binding of protein tyrosine phosphatase SHP2 (Src homology domain 2-containing 
tyrosine phosphatase 2) (Pluskota et al., 2000). ICAM-1 is also speculated to associate with 
adapter proteins such as Grb2, SOS, and Shc (Gardiner and D'Souza, 1999). The activation of 
receptor-associated tyrosine kinases can lead to downstream activation of the mitogen-
activated protein (MAP) kinase pathway, including extracellular signal-regulated kinase 1 and 
2 (ERK1, ERK2) (Fig.7).   
ICAM-1 cross-linking by antibodies on lymphoma cells induces tyrosine 
phosphorylation of several cellular proteins including the Src family kinase p53/p56
lyn
 
(Holland and Owens, 1997), as well as the cyclin-dependent kinase cdc2, a cell cycle 
regulator (Chirathaworn et al., 1995). Engagement of ICAM-1 on a B cell line with soluble 
fibrinogen elicits phosphorylation of pp60Src (Gardiner and D'Souza, 1999). On brain 
endothelial cells, ICAM-1 cross-linking by antibodies induces tyrosine phosphorylation of the 
cytoskeletal-associated protein cortactin (Durieu-Trautmann et al., 1994), as well as Rho 
activation and Rho-dependent tyrosine phosphorylation of FAK, paxillin, and p130cas 
(Etienne et al., 1998). 
Information of ICAMs association with actin or actin-binding cytoskeletal protein is 
relatively limited as compared with integrins. However, ICAM-1 is found to prominently 
accumulate into the cellular projections of some B cell lines, and it colocalizes with α-actinin 
(Carpen et al., 1992), an actin-binding cytoskeletal protein, or ezrin (Heiska et al., 1998), a 
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cytoplasmic linker molecule between plasma membrane components and the actin-containing 
cytoskeleton (reviewed by Mangeat et al., 1999). It does not bind to the cytoskeletal proteins 
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Figure 7. Through β2 integrins-ICAM-1 interactions, and the formation of ICAM-1 
multimers within the cell membrane, signal transduction is initiated. ICAM-1 is 
implicated to be phosporylated by Src family kinases. Phosphorylated ICAM-1 may 
transduce signals by association with adaptor proteins, such as Grb2, SOS, and Shc, 
or tyrosine phosphatases, such as SHP-2. The activation of these receptor-
associated tyrosine kinases/phosphatases can lead to downstream activation of the 
mitogen-activated protein (MAP) kinase pathways. Activation of MAPK results in 
transcription factor activation, which leads to cytokine production, increased 
membrane protein expression, reactive oxygen production, and altered patterns of 
cell proliferation etc.  
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talin, tensin, and vinculin in transfected COS cells. Via its membrane proximal region of the 
cytoplasmic domain, ICAM-1 was reported to associate with α-actinin (Carpen et al., 1992) 
and ezrin (Heiska et al., 1998). In addition, recent data indicates that the small GTPase Rho 
regulates the clustering of ICAM-1, as well as E-selectin and VCAM-1 on the surface of 
endothelial cells, probably by enhancing their association with the ERM 
(ezrin/radixin/moesin) family members (Wojciak-Stothard et al., 1999). 
 
2.1.4. Function 
 
As an adhesion molecule, ICAM-1 participates in trafficking of inflammatory cells, in 
leukocyte effector functions, and in adhesion of antigen-presenting cells to T lymphocytes 
during antigen presentation. It may play a pathogenetic role in rhinovirus infections. 
Moreover, ICAM-1 also participates in signal transduction pathways through “outside-in” 
signaling (Hubbard and Rothlein, 2000). 
The recognition of ICAM-1 by β2 integrins results in the adhesion of activated 
leukocytes to the endothelium and in the extravasation of leukocytes to sites of inflammation. 
The extravasation of leukocytes may also occur through a process involving ICAM-1 and the 
plasma protein fibrinogen (Altieri, 1999). In this process, the integrin-bound fibrinogen 
interacts with ICAM-1, mediating the bridging between blood cells and the endothelial cells. 
ICAM-1 also functions as a costimulatory molecule on antigen-presenting cells to activate 
MHC class II restricted T-cells, and on other cell types in association with MHC class I to 
activate cytotoxic T-cells. 
In addition to its role in cell/microbial adhesion, ICAM-1 may also participate in 
signal transduction across cell membranes. A signal may pass from the outside of the cell to 
the inside in response to β2 integrin binding, fibrinogen ligation, or antibody cross-linking, 
with resulting activation of second messenger systems and gene transcription which leads to 
cytokine production, membrane protein expression, cell proliferation, and cell survival 
(Hubbard and Rothlein, 2000) (Fig. 7).   
Studies on ICAM-1-deficient mice, however, exhibit contradictive data. Two ICAM-1 
deficient mouse strains have been generated so far, one with disruption of exon 4 encoding 
domain 3 (Xu et al., 1994), the other exon 5 encoding domain 4 (Sligh et al., 1993). Two 
studies on these mice show multiple abnormalities of inflammatory response, including 
impaired neutrophil emigration in response to chemical peritonitis, resistance to septic shock, 
and decreased contact hypersensitivity reaction (Sligh et al., 1993; Xu et al., 1994). However, 
other studies on these mutant mice showed normal neutrophil emigration during chemical- or 
pathogen-induced pneumonia, while the symptoms in wild type mice were substantially 
reduced by anti-ICAM-1 monoclonal antibody or ICAM-1 antisense oligonucleotide 
treatment (Kumasaka et al., 1996; Qin et al., 1996). It is not clear whether these marked 
differences result from compensation in the deficient mice, since ICAM-1 is not the only 
cellular ligand for β2 integrins. However, it should be noted that the mouse strain with mutant 
exon 5 was earlier found to express different isoforms of membranous ICAM-1 in several 
tissues (King et al., 1995), and the strain with disrupted exon 4 was recently reported to 
contain several isoforms of soluble ICAM-1 in the serum in similar amounts as the wild type  
mice (van Den Engel et al., 2000). These facts make intepretation of the experimental data 
obtained from these mutant mice more difficult.      
The regulation and significance of soluble ICAM-1 are poorly understood, but soluble 
ICAM-1 is increased in many pathological conditions (reviewed by Gearing and Newman, 
1993). It is conceivable that soluble ICAM-1 would bind to β2 integrins with sufficient 
affinity and avidity, and function as a physiological inhibitor of β2 integrin/ICAM-1-mediated 
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leukocyte adhesion to regulate local cellular responses. On the other hand, it could also 
activate β2 integrins (Kotovuori et al., 1999). 
 
2.2. ICAM-2 (CD102) 
  
2.2.1. Structure and binding partners 
 
ICAM-2 is a glycoprotein of 60 kDa with a polypeptide chain of 28 kDa composed of 
two Ig domains, a transmembrane domain, and a cytoplasmic tail (Nortamo et al., 1991a; 
Staunton et al., 1989) (Fig. 4). The two Ig domains of ICAM-2 are 34% identical in amino 
acid sequence to the two amino terminal domains of ICAM-1. There are six N-linked glycans 
in ICAM-2 Ig domains. All the other ICAM genes are clustered in chromosome region 
19p13.2, except for the ICAM-2 gene which is located on chromosome 17q23-25 (Hayflick et 
al., 1998). ICAM-2 seems to exist on the cell surface as a monomer (Reilly et al., 1995). 
Soluble ICAM-2 in serum has not been described yet. 
ICAM-2 is a cellular ligand for CD11a/CD18 (Staunton, et al., 1989) and 
CD11b/CD18 (Xie et al., 1995) (Table 2). Site-directed mutagenesis of ICAM-2 indicates that 
glutamate
37
, corresponding to glutamate
34
 in ICAM-1, is a critical residue for CD11a/CD18 
binding (Casasnovas et al., 1999) (Fig. 6C and D). 
ICAM-2 is the first ICAM for which a crystal structure has been solved (Casasnovas 
et al., 1997) (Fig. 6C). The crystal structure shows that glutamate
37
 is on a flat surface on the 
CFG face of domain 1, which, together with the later characterized crystal structure of ICAM-
1 (see section 2.1.1.), suggests a different type of binding interface for I domain integrin than 
non-I domain integrins (reviewed by Wang and Springer, 1998). Another interesting feature 
of the ICAM-2 structure is that the three N-linked oligosaccharides in domain 2 may form a 
tripod-like array on the bottom of domain 2 (Casasnovas et al., 1997) (Fig. 6D), which may 
maintain ICAM-2 in a configuration most accessible to LFA-1 on another cell. This 
positioning may partly compensate for the small size of ICAM-2 (Wang and Springer, 1998).            
 
2.2.2. Expression 
 
ICAM-2 is constitutively expressed at high level on endothelial cells, and at lower 
levels on leukocytes (Nortamo et al., 1991a) and platelets (Diacovo et al., 1994). It is not 
inducible by inflammatory mediators (Nortamo et al., 1991b). 
 
2.2.3. Cytoplasmic associaton 
 
ICAM-2 is found to cluster into projected regions of natural killer cells, and 
colocalizes with ezrin (Helander et al., 1996). Furthermore, ICAM-2 is reported to bind to 
ezrin (Heiska et al., 1998) and α-actinin (Heiska et al., 1996). 
 
2.2.4. Function 
 
ICAM-2 has been shown to participate in leukocyte traffic, in antigen presentation, 
and in platelet-neutrophil interaction (reviewed by de Gaetano et al., 1999). Since its 
expression is refractory to cytokine stimulation, ICAM-2 might mediate lymphocyte 
recirculation into secondary lymphoid tisssues. As the smallest ICAM, ICAM-2 binding to 
integrins may shorten the distance between membranes compared to ICAM-1 and may allow 
integrins to cooperate more closely with smaller adhesion molecules such as CD2/LFA-3 
(Hayflick et al., 1998). 
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Another function of ICAM-2 may be stimulating the integrin activity. Our group has 
shown that a peptide P1, derived from the first domain of ICAM-2, activates β2 integrins (Li 
et al., 1995), and increases the cytotoxicity of natural killer cells (Li et al., 1993). Soluble 
ICAM-2 increases the affinity of β2 integrins for ICAM-1 on T lymphocytes (Kotovuori et 
al., 1999).  
ICAM-2-deficient mice are recently described (Gerwin et al., 1999). Total leukocyte 
counts and leukocyte subset numbers are unaltered compared with wild type mice. Although 
platelet counts are not reduced, there is a reduction in megakaryocyte progenitors in the bone 
marrow of the ICAM-2-deficient mice. Lymphocyte homing to lymphoid tissues is 
unaffected. Interestingly, during allergic lung inflammation, there is a delayed increase in 
eosinophils in the airway lumen and a prolonged presence of eosinophil infiltrates in lung 
tissue, suggesting that ICAM-2 participates in the traffic of eosinophils from the blood to the 
airway lumen (Gerwin et al., 1999). 
 
2.3. ICAM-3 (CD50) 
 
2.3.1. Structure and binding partners 
 
ICAM-3 is a glycoprotein of 124 kDa composed of five Ig domains, a transmembrane 
domain, and a short cytoplasmic tail (Fig. 4). It is most closely related to ICAM-1, with an 
overall 47% amino acid identity, rising to 77% percent in the second domain (Fawcett et al., 
1992). Its amino terminal two domains show overall 31% amino acid identity to ICAM-2 
(Vazeux et al., 1992). ICAM-3 has 15 putative N-linked glycosylation sites. Unlike ICAM-1, 
there is no bend visible by rotary shadowing electron microscopy (Vazeux et al., 1992). 
Neither is there evidence that ICAM-3 forms dimers. Soluble ICAM-3 is found in normal 
human serum and is elevated in systemic lupus erythematosus (Pino-Otin et al., 1995). 
ICAM-3 is a cellular ligand for CD11a/CD18 (de Fougerolles and Springer, 1992) and 
CD11d/CD18 (Van der Vieren et al., 1995) (Table 2). Site-directed mutagenesis of the first 
domain of ICAM-3 identified a similar CD11a/CD18 binding site as in ICAM-1, and -2 
(Holness et al., 1995). Notably, detailed molecular analysis suggests that the binding sites on 
the I domain of CD11a/CD18 for ICAM-1, -2, and -3 are overlapping but not identical. 
Moreover, the binding faces for CD11a/CD18 on top of ICAM-1, -2, and -3 appear to be 
distinct (reviewed by Binnerts and van Kooyk, 1999). It is therefore tempting to speculate that 
these differences in the molecular interaction of CD11a/CD18 with ICAM-1, -2, or -3 
underlie the different affinities of their interactions. Soluble ICAM-1 is reported to bind to 
immobilized CD11a/CD18 with an affinity of ~60 nM, while the affinity of soluble ICAM-3 
for immobilized CD11a/CD18 is 9 times weaker (~550 nM) (Woska et al., 1998). However, 
in another study testing soluble CD11a/CD18 binding to immobilized ICAM-1, the affinity 
was much weaker (~500 nM) (Tominaga et al., 1998). Despite of this discrepancy, it is 
generally accepted that ICAM-1 bears the highest affinity for CD11a/CD18 among ICAMs. 
In addition, a C-type lectin exclusively expressed on dendritic cells, DC-SIGN, was 
recently identified to act as a novel high affinity ICAM-3 receptor by binding to the 
carbohydrate moieties of ICAM-3 (Geijtenbeek et al., 2000) (Table 2).        
 
2.3.2. Expression 
 
ICAM-3 is strongly expressed on resting lymphocytes, which suggests that it is 
involved in early activation steps of the inflammatory response. Upon activation of 
lymphocytes with phorbol ester, ICAM-3 expression shows little, if any, increase, whereas 
ICAM-1 expression was greatly increased (de Fougerolles and Springer, 1992). 
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Figure 8. Models of ICAM-3 mediated signaling. In A, low-affinity 
interaction of LFA-1 on the T cell with ICAM-3 on the target cell (1), induces 
redistribution/clustering of LFA-1 (2), to prime LFA-1 for activation. When 
upon anti-CD3 triggering or antigen recognition, intracellular signals enhance 
the affinity of LFA-1 for ICAM-1 (3), stable LFA-1/ ICAM-1 cell-cell 
interaction will be induced (4). Ultimately, signals transmitted by LFA-1 upon 
ICAM-1 binding result in the induction of T cell proliferation, cytotoxicity, 
and gene expression (5) (Adapted from Bleijs et al., 2000). In B, DC-
SIGN/ICAM-3 interactions form a first contact between dendritic cells and T 
cells (1). This transient interaction facilitates the formation of low-avidity 
interactions in which LFA-1/ICAM-1 also participates, giving rise to loose 
antigen-independent dendritic cell-T cell clustering (2). After TCR ligation 
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(3), signals result in high-avidity LFA-1/ICAM-1 and CD2/LFA-3 
interactions, giving rise to a further stabilization of the immunological 
synapse in which the smaller TCR/MHC/peptide and CD2/LFA-3 form the 
center and LFA-1/ICAM-1 form the outer ring (4) (Adapted fromGeijtenbeek 
et al., 2000).   
 
2.3.3. Cytoplasmic association  
 
ICAM-3 has been regarded as a signaling molecule ever since its discovery (Fig. 8). 
The 37-amino-acid cyptoplasmic tail of ICAM-3 has several serine (Hayflick et al., 
1997;Lozano et al., 1992) and tyrosine residues (Skubitz et al., 1995), which are 
phosphorylated upon phorbol ester treatment or TCR cross-linking. Phosphorylation of serine 
residues is dependent on protein kinase C (Hayflick et al., 1997; Lozano et al., 1992). 
Mutation of serine residues abolished T lymphocyte function such as cytokine production, 
cell aggregation, and cell spreading (Hayflick et al., 1997). Other studies have shown that 
cross-linking of ICAM-3 induces tyrosine phosphorylation (Arroyo et al., 1994; Feldhaus et 
al., 1998; Juan et al., 1994), intracellular calcium flux via tyrosine kinases p56
lck
 and p59
fyn
 in 
leukemia cell lines (Juan et al., 1994), increased phosphatidylinositol hydrolysis and 
phosphorylation of phospholipase Cγ1 in T lymphocytes (Berney et al., 1999). Reorganization 
of the cytoskeleton was dependent on protein kinase C and tyrosine kinase activities in 
neutrophils (Feldhaus et al., 1998). 
Activated T lymphocytes are polarized, motile cells (reviewed by Sanchez-Madrid and 
del Pozo, 1999). Moesin, a member of the ERM family, has been shown to interact with the 
cytoplasmic region of ICAM-3, and was redistributed together with ICAM-3 to the uropod, a 
membrane protrusion at the end of a migrating lymphocyte opposite the direction of 
locomotion, during cell polaization (Serrador et al., 1997). In contrast, ezrin, another ERM 
family member, did not bind to ICAM-3 (Heiska et al., 1998). Redistribution of ICAM-3 and 
moesin to uropods was induced by chemokines, and might be dependent on 
phosphatidylinositol 3-kinase (Vicente-Manzanares et al., 1999), and/or Rho GTPases (del 
Pozo et al., 1999).  
 
2.3.4. Function 
 
As an adhesion molecule, ICAM-3 participates in lymphocyte aggregation. But more 
importantly, ICAM-3 seems to function as a signal transducer on leukocytes, and has been 
implicated in the initiation of the immune response (de Fougerolles and Springer, 1992; 
Fawcett et al., 1992). It acts as a co-stimulatory molecule for T lymphocyte activation and 
proliferation through its interaction with β2 integrins (Hernandez-Caselles et al., 1993) (Fig. 
8A), or DC-SIGN (Geijtenbeek et al., 2000) (Fig. 8B). It enhances the T lymphocyte adhesion 
to endothelial cells and extracellular matrix, probably by inducing the activation of β1 and β2 
(Bleijs et al., 2000) integrins. Moreover, ICAM-3 has been implicated to elicit apoptotic 
signal independent of Fas/FasL and TNFα/TNF receptor-activated pathways in leukocytes 
(Lopez-Briones et al., 1998; Stucki et al., 2000).  
 
2.4. ICAM-4 (LW blood group antigen) 
 
2.4.1. Structure and binding partners 
 
ICAM-4 was originally called the LW (Landsteiner-Wiener) blood group antigen, but 
its primary structure revealed significant similarity to ICAMs, with an overall 30% amino 
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acid identity to the first two domains of ICAM-1. It is a 42 kDa glycoprotein composed of 
two Ig domains, a transmembrane domain, and a short cytoplasmic domain. It contains four 
putative N-glycosylation sites (Bailly et al., 1994) (Fig. 4).  
ICAM-4 is a cellular ligand for β2 integrins CD11a/CD18 and CD11b/CD18 (Bailly et 
al., 1995) (Table 2). Our group has shown recently that the interactions are through the I 
domains of these integrins (unpublished result). CD11a/CD18 has been found to bind to the 
first domain, whereas CD11b/CD18 binding sites encompass both domains of ICAM-4 
(Hermand et al., 2000). Site-directed mutagenesis has been carried on ICAM-4. Unlike the 
other ICAMs, ICAM-4 does not contain the otherwise conserved glutamate residue in the first 
domain, but it is replaced by an arginine
52
 residue. However, mutation of arginine
52
 back to 
glutamate did not affect CD11a/CD18 binding. Instead, other residues on the CFG face of 
domain 1 are involved in CD11a/CD18 binding, suggesting  different binding properties of 
ICAM-4 to CD11a/CD18 than ICAM-1, -2, and -3 (Hermand et al., 2000).  
 
2.4.2. Expression 
 
ICAM-4 is exclusively expressed on the red cell lineage of haematopoietic cells 
(Bailly et al., 1994).  
 
2.4.3. Function 
 
The physiological function of ICAM-4 is currently unknown. Its interaction with β2 
integrins might play some role in the red cell turnover to eliminate senescent red cells by 
spleen macrophages in the spleen red pulp or during erythroid maturation to retain immature 
erythroid precursors in the bone marrow (Bailly et al., 1995; Gahmberg, 1997a, b).              
 
3. ROLE OF IgSF ADHESION MOLECULES IN THE CNS 
 
3.1. Neuronal IgSF adhesion molecules in development and plasticity of the CNS 
 
The human brain contains about 10
12
 neurons, each of which makes an average of 
1000 contacts, or synapses, with other neurons, resulting in a complex but highly specific 
network of 10
15
 synapses that governs all brain functions, from simple motor tasks to 
sophisticated emotional and cognitive behavior. 
The extraordinary specificity of connections in the adult brain is generated in seven 
consecutive steps: (1) Initially, neural precursor cells are generated from ectodermal cells. (2) 
Neural precursors develop into glia cells and immature neurons. (3) Immature neurons 
migrate from the zone of active proliferation to their final destination. (4) Once arrived in 
their target area, immature neurons form axons which grow, often over considerable 
distances, into the target region with which (5) the corresponding nerve cell is destined to 
make contact. (6) After a growing axon has reached its target area, it selects individual target 
cells from a large number of possible candidates, and a synapse is formed at the initial site of 
contact between the axon and the target cell. (7) Synapses formed by these processes undergo 
dynamic changes in synaptic strength that are dependent on environmental stimuli and 
experience, and may be the basis of memory and learning mechanisms (synaptic plasticity) 
(reviewed by Brose, 1999). 
Brain plasticity and the mechanisms controlling plasticity are central to learning and 
memory as well as to the recovery of function after brain injury. Cell adhesion molecules are 
good candidate molecules to take part in neuronal connections and brain plasticity (Murase 
and Schuman, 1999). Cell adhesion molecules mediate adhesion of cells to other cells as well  
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Figure 9. Schematic structure of neuronal adhesion molecules of IgSF (A). *: 
expressed in invertebrates. B shows the crystal structures of the first Ig domain 
of NCAM (top), and the first two FnIII domains of neuroglian (bottom). C 
depicts the molecular interactions of these molecules found on vertebrate axons. 
Looped single arrows represent homophilic binding. Double-headed arrows 
represent heterophilic binding; when a square is also present on the arrow, the 
binding occurs within the same membrane plane (cis). 
 
as to components of the ECM, and are thereby well suited to influence cell migration, neurite 
extension, and fasciculation, and possibly formation of synapses in the brain. Moreover, the 
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binding of cell adhesion molecules has been shown to activate intracellular signal 
transduction cascades which in turn initiate cellular responses including neurite outgrowth 
(Walsh and Doherty, 1997). In addition, the expression of certain cell adhesion molecules 
may be influenced by neuronal activity (Butler et al., 1998). Thus, cell adhesion molecules, 
by mediating “outside-in” and/or “inside-out” signaling, can translate rapid signaling events 
into structural changes and vice versa. Ironically, however, cell adhesion molecules can also 
cause disturbances that drive the development of brain pathology in conditions such as AD 
and MS (Cotman et al., 1998). 
There are several families of adhesion molecules involved in the CNS development. 
However, only members of the IgSF, especially the neural cell adhesion molecule (NCAM) 
and L1, will be dealt with in this review, while members of the other families such as 
integrins (Connolly and Tully, 1998), ECM proteins (Rauch, 1997), cadherins (Shapiro and 
Colman, 1999), and proteoglycans (Grumet et al., 1996) will not be covered here. 
NCAM was the first neuronal cell adhesion molecule of IgSF to be identified. The 
extracellular part of NCAM consists of five Ig domains, and two fibronectin type III (FnIII) 
homology domains (Fig. 9A and B). By alternative splicing, three main forms of NCAM 
arise, termed NCAM-180 (NCAM-A), NCAM-140 (NCAM-B) and NCAM-120 (NCAM-C). 
NCAM-180 and NCAM-140 are transmembrane forms differing in their cytoplasmic 
domains, whereas NCAM-120 is attached to the membrane via a glycosylphosphatidylinositol 
anchor. In addition, soluble forms of NCAM, generated by truncation, proteolysis or 
shedding, exist (Ronn et al., 2000). NCAM may be further modified by alternative splicing in 
exons encoding the extracellular part of the molecule. Notably, the insertion of 10 amino 
acids encoded by the variably alternatively spliced exon (VASE) in Ig domain 4 may 
influence NCAM-functions in a developmentally regulated manner as transcripts containing 
the VASE-sequence markedly increases during development. Further variability among 
NCAMs is generated at the post-translational level. Homopolymers of α-2, 8-linked sialic 
acid residues constitute up to 30% of the highly sialyated NCAM isoforms. This unusual 
carbohydrate polymer is a potent regulator of cell interactions (reviewed by Ronn et al., 2000; 
Cremer et al., 2000). 
NCAM is the founder member of a large family of cell surface glycoproteins that 
share similar structural motifs. These glycoproteins have been grouped based on the 
respective number of each type of Ig domain and FnIII domain (Fig. 9A). In vertebrates, 
members of this family include the L1 subgroup: L1, NgCAM (neuron-glia cell adhesion 
molecule), NrCAM (NgCAM-related cell adhesion molecule); axonin-1/TAG-1 (transiently 
expressed axonal surface glycoprotein) subgroup: axonin-1, BIG-1 (brain-derived Ig 
molecule), BIG-2, F11; and NCAM (Walsh and Doherty, 1997). 
L1 is a 200 kDa cell surface molecule composed of six Ig domains followed by five 
FnIII domains, a single-pass transmembrane domain, and a cytoplasmic tail (Fig. 9A). Two 
alternatively spliced forms of L1 are known: a neuronal form that contains a four-amino acid 
RSLE (arginine, serine, leucine, glutamate) sequence and an RSLE-minus form expressed in 
non-neuronal cells such as Schwann cells, melanocytes, and lymphocytes (Kenwrick et al., 
2000). 
Both NCAM and L1 are widely expressed on neural tissues during development. They 
each show a dramatically complex pattern of extracellular interactions ranging from 
homophilic binding through Ig domains, to heterophilic interactions with integrins, other IgSF 
members, ECM proteins, or proteoglycans (reviewed by Brummendorf and Rathjen, 1996) 
(Fig. 9C). NCAM-NCAM binding involves all five Ig domains, and they interact pairwise in 
an antiparallel orientation, whereas L1-L1 interaction is through its second Ig domains. 
Homophilic interaction of NCAM or L1 induces a cis-interaction with the FGF receptor, and 
triggers a phospholipase Cγ-dependent intracellular signaling cascade indirectly (Walsh and 
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Doherty, 1997) (Fig 10). Moreover, both molecules have been found to associate with non-
receptor tyrosine kinases such as Src and Src-related tyrosine kinase Fyn via their cytoplasmic 
tails, indicating their direct involvement in “outside-in” signaling cascades in neurons 
(reviewed by Crossin and Krushel, 2000; Walsh and Doherty, 1997). In addition, the 
cytoplasmic tails of NCAM-180 and L1 interact with actin filaments via the cytoskeletal 
proteins spectrin (Pollerberg et al., 1987) and ankyrin (Davis and Bennett, 1994) respectively, 
which may be modulated by tyrosine phosphorylation (Kenwrick et al., 2000). 
 
 
 
 
Figure 10. Schematic diagram of signaling events associated with CAM-mediated 
neurite outgrowth. The FGF (fibroblast growth factor) receptor is biochemically 
activated following a cis interaction in the plane of the plasma membrane with 
NCAM or L1. The enzyme PLCγ (phospholipase Cγ) binds to phosphorylated 
tyrosine residues on the FGF receptor, and this ultimately leads to generation of 
DAG (diacylglycerol), which is converted to arachidonic acid (AA) by DAG lipase. 
It is likely that AA acts on calcium channels to produce calcium influx. 
Downstream events from this appear to be activation of calmodulin (CaM) kinase, 
and finally the neurite outgrowth response (Adapted from Walsh and Doherty, 
1997).  
 
3.1.1. Neuronal migration, differentiation, and axonal guidance of the CNS 
 
One of the remarkable features of CNS development is the extensive migration of 
progenitor cells to the location where the post-mitotic, terminally differentiated cells reside in 
the mature brain. Neurons and glia are predominately derived from progenitor cells located 
adjacent to the lumen of the neural tube. These regions, known as the ventricular zone and 
subventricular zone, are composed of proliferating cells. The two daughter cells resulting 
from a cell division may each re-enter the cell cycle, one may re-enter the cell cycle and the 
other may leave the cell cycle, or both may exit the cell cycle. Those cells that exit the cell 
cycle begin to differentiate. The involvement of IgSF adhesion molecules in the control of 
neural stem cell proliferation and differentiation has not been much studied. However, NCAM 
has been shown recently to promote hippocampal progenitor cell differentiation to a neuronal 
phenotype (Amoureux et al., 2000). As cells differentiate, they also migrate away from their 
site of birth to where they will reside in the mature nervous system.  
Two major pathways of cell migration have been identified during early development: 
(1) radial, from the ventricular zone out toward the surface of the neural tube, and (2) 
nonradial or tangential, which is parallel to the surface of the neural tube. Radial migration 
was the first pathway of migration to be identified and is the best characterized. Radial cell 
migration is also known as glial-guided cell migration because the neural stem cells migrate 
along specialized glial cells known as radial glia (reviewed by Hatten, 1999). In vitro and in 
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vivo studies of radial cell migration have identified a number of molecules that participate in 
this pathway of migration, including members of IgSF such as NCAM, L1, and related 
molecules (Brummendorf and Rathjen, 1995). For instance, NCAM and its polysialic acid 
moiety are abundantly expressed along this pathway from the subventricular zone to the 
olfactory bulb. NCAM is postulated to promote the rostral migratory pathway, in which 
neural progenitor cells migrate to populate the olfactory bulb (Rousselot et al., 1995). Various 
NCAM knock-out mouse models and a polysialic acid-depleted mouse model presented a 
similar phenotype that includes a reduced olfactory bulb, which has been attributed to 
decreased migration of the subventricular zone cells to their target (Walsh and Doherty, 
1997). 
Once a neuron reaches its final destination, it starts to make connections with other 
cells by projecting an axon to its target cells. A key event in this process is the guidance of the 
axon to its target via the action and orientation of the growth cone, a hand-shaped 
membranous structure with several long filopodia at the tip of a growing axon. It is 
responsible for sensing the local environment and moves toward the neuron's target cell (Suter 
and Forscher, 1998). As such, the growth cone must express receptors for the guidance 
molecules that are present in its microenvironment, and the resulting ligand-receptor 
interactions must be able to influence the motility of the growth cone. Axonal pathfinding 
requires the integration of a number of different cues stimulating various signal transduction 
pathways that can either promote or inhibit axonal outgrowth. Several IgSF members, such as 
NCAM, L1, and related molecules, have been implicated in axonal outgrowth and growth 
cone guidance during the development of the nervous system, by virtue of their restricted 
expression patterns and their ability to modulate cell interactions (Walsh and Doherty, 1997). 
Evidence that these molecules play an important role in axonal growth and guidance has been 
obtained by a variety of experimental paradigms including direct demonstration that the 
molecule can promote growth in vitro, antibody perturbation, or examination of the 
consequences of both loss- and gain-of-function mutants.  
Purified IgSF adhesion molecules are excellent substrates for axonal growth, and this 
is particularly true for L1. Studies with blocking antibodies suggest that both the substrate-
coated and cellular L1 promote axonal growth primarily via a homophilic interaction with L1 
on the neuron (Walsh and Doherty, 1997). For instance, antibodies to L1 inhibit axonal 
growth over monolayers of L1-transfected cells or cultured glial cells (Williams et al., 1992), 
and cause perturbations in the growth of retinal ganglion cell axons in the rat retina (Brittis et 
al., 1996). Furthermore, L1 knock-out mice make errors in corticospinal axon guidance 
(Cohen et al., 1998), and show developmental defects in the hippocampus and corpus 
callosum (Demyanenko et al., 1999). Additionally, the ability of axons to cross the floor plate, 
a specialized region of the ventral-most margin of the CNS, is dependent on a trans 
interaction between axonin-1 on the commissural neurons with NrCAM on the floor plate 
cells (Fitzli et al., 2000). Moreover, axonin-1 has previously been shown to in cis interact 
with NgCAM on the same neuron, and the cis binding facilitates the former to function as an 
axonal growth-promoting receptor (Kunz et al., 1998). Overall, the above studies clearly 
demonstrate that IgSF adhesion molecules can promote axonal growth and guidance via both 
homophilic- and heterophilic-binding mechanisms and that perturbation of their function can 
be associated with defects in axonal growth, fasciculation, and guidance.   
Directed axonal outgrowth occurs by the coordination of two processes. The first 
process is the protrusion of the leading edge of the growth cone. This step depends on the 
assembly of F-actin and its attachment to the membrane adhesion receptors that, in turn, bind 
to the substrate on which the growth cone moves. The second process is axonal extension, 
which occurs by the engorgement of microtubules into the periphery and the consolidation of 
these microtubules to form the nascent axon. When a growth cone turns towards an attractive 
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substrate, adhesion molecules expressed on growth cone bind to the target substrate, make 
functional linkage with the underlying actin cytoskeleton and stablize it. Stabilization of distal 
actin networks generates tension inside the growth cone which promotes microtubule 
extension and also protrusive leading edge growth, and thus regulates the rate and direction of 
axonal growth (Suter and Forscher, 1998). Hence, adhesion molecules expressed on the 
growth cone function as a “molecular clutch” to mediate substrate-cytoskeletal coupling 
during axonal outgrowth. The cytoplasmic tails of NCAM-180 (Pollerberg et al., 1987) and 
L1 (Davis et al., 1994) interact with actin filaments via the cytoskeletal proteins spectrin and 
ankyrin, respectively. Recent findings suggest distinct roles in the growth cone for L1 and 
NCAM-180 at different steps of neurite outgrowth: L1 functions in neurite extension, whereas 
NCAM-180 functions in growth cone protrusion (Takei et al., 1999). 
NCAM and L1 modulate growth cone function by activating signaling cascades 
involving tyrosine kinases (Fig. 10). There is accumulating evidence that regulated tyrosine 
phosphorylation is a fundamental mechanism for controlling growth cone motility. NCAM 
and L1 mediated axonal outgrowth requires the activation of the FGF receptor tyrosine kinase 
cascade, with the consequent activation of phospholipase Cγ to generate diacylglycerol, 
diacylglycerol is then hydrolyzed by diacylglycerol lipase to form arachidonic acid, 
arachidonic acid induces increase in calcium channel permeability, and influx of Ca
2+
 finally 
activates the Ca
2+
/calmodulin-activated kinase (Walsh and Doherty, 1997). 
 
3.1.2. Synaptogenesis and synaptic plasticity of the CNS 
 
Synapses are asymmetric cell-cell contacts, typically formed between the presynaptic 
axon terminal of a “sending” nerve cell and the postsynaptic dendrite, soma, or, in some 
cases, the axon of a “receiving” nerve cell. The presynaptic axon terminal is specialized for 
complex membrane trafficking mechanisms that underlie regulated secretion of 
neurotransmitters. It contains a diverse set of proteins, many of which are highly specific for 
presynaptic structures. The axon terminal usually faces a postsynaptic structure that is 
uniquely specialized for signal transduction, containing a scaffold of transmitter receptors, ion 
channels, and a multitude of intracellular signal transduction molecules. Again, a large 
number of postsynaptic proteins are specifically targeted to this structure, and are not present 
in other parts of the cell (Brose, 1999).  
In principle, the synaptogenesis process can be divided into two steps. First, the intitial 
contact between an axonal growth cone and a target cell is made. This process is extremely 
specific as any given axon makes contacts to only a selected group of target cells. The initial 
contact is most likely mediated by cell adhesion molecules. Given the large number of 
different neuronal cell types in the brain, the adhesion system mediating initial target cell 
recognition by an axon must be highly sophisticated. It must identify the respective axon and 
target cell, allowing the interacting structures to discriminate appropriate partner cells from 
wrong ones. Such recognition requirements can be met only by families of polymorphic 
adhesion molecules that offer sufficient combinational possibilities to guarantee the reliable 
distinction between various cell types in a given brain region. In the second step, specific 
recruitment of pre- and post-synaptic proteins leads to the formation of a synapse at the site of 
initial contact. The asymmetry of synapses is likely to be mediated at least in part by 
heterotypic trans-synaptic signalling. In fact, heterotypic cell adhesion processes must be 
postulated in order to explain the specific and differential recruitment of pre- and postsynaptic 
protein components to their respective subcellular compartments (Brose, 1999). 
Once formed, a synapse is a highly dynamic structure. During early brain 
development, a large number of newly generated synapses are eliminated while others are 
strengthened. This process of synapse elimination and strengthening depends partly on 
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external stimuli and synaptic activity. It represents an essential step in the establishment of 
finely tuned neuronal networks and topographic maps. Similar activity-dependent dynamic 
changes in synaptic strength occur in the adult brain, where they are thought to underlie 
learning and memory formation (Murase and Schuman, 1999).  
Several cell adhesion molecules have been implicated in synaptic function in the 
mammalian brain. Importantly, NCAM and L1 have been shown to affect long-term 
potentiation (LTP) in rat hippocampal slices, and passive avoidance learning in the chicken 
(Luthl et al., 1994). LTP is a long-lasting increase in synaptic transmission inducible by high-
frequency stimulation of the CNS nerve fibers in vitro or in vivo. LTP shares many 
characteristics of learning, and has been widely used in order to identify and understand 
molecular mechanisms presumed to control synaptic changes in learning and memory. 
Blockade of NCAM by local injection of NCAM antibodies or blockade of NCAM-L1 
interactions by oligomannosidic carbohydrates or synthetic peptides inhibited the induction or 
early maintenance of LTP in the CA1 region of hippocampal slices in vitro (reviewed by 
Cremer et al., 2000; Ronn et al., 2000). In addition, polysialylated NCAM has recently been 
shown to be partly associated with developing synapses in hippocampus (Seki and Arai, 
1999). Mice lacking NCAM-180 or expressing polysialic acid deficient NCAM exhibit 
aberrant mossy fiber innervation and ectopic synaptogenesis in the hippocampus, which might 
account for the spatial-learning deficit noted in mice tested with the Morris water maze. In 
support of this, organotypic slice cultures of hippocampus prepared from the NCAM 
knockout mice exhibit a decaying LTP compared with LTP in wild-type mice, and enzymatic 
removal of polysialic acid from the latter completely prevents LTP (Muller et al., 1996). L1-
null mice perform poorly in a spatial learning paradigm (Fransen et al., 1998). These data 
clearly suggest a role for IgSF members in the immediate synaptic plasticity associated with 
learning and memory. 
 
3.2. IgSF adhesion molecules in immune diseases of the CNS 
 
3.2.1. Infectious diseases: encephalitis 
 
Although the brain is well protected from infectious agents by meninges and the BBB, 
these are not absolute barriers. Infectious agents like bacteria and viruses can invade the brain 
indirectly through the blood flow from a primary source of infection, or directly as the result 
of brain trauma or surgery. A few viruses can spread along peripheral nerves to reach the 
CNS. Bacterial agents usually cause purulent reactions with polymorphonuclear leukocytes, 
while viruses provoke a lymphocytic response.  Infections by these pathogens lead to diseases 
such as meningitis, encephalitis, or abscesses etc. The consequences of a CNS infection 
depend on the pathogenesis and location of lesions. Patients may suffer from hydrocephalus 
after obstruction of the cerebrospinal fluid (CSF) flow, edema and consequently increased 
intracranial pressure, permanent damage to cranial nerves, focal and generalized signs due to 
neuronal destruction, or thrombosis due to vasculitis (Roos, 1999).         
Encephalitis is an acute infection of brain parenchyma characterized clinically by 
fever, headache, and an altered level of consciousness. There may also be focal or multifocal 
neurological deficits such as movement disorders, mental retardation, and seizure activity. 
Encephalitis is usually caused by viral infection. Such viruses include HIV, polio, rabies, and 
herpes simplex viruses (HSV) etc. Viruses can invade into the brain haematogenously from 
the peripheral infection sites, or, in cases of rabies and HSV, spread along peripheral nerves. 
Specific viruses affect specific anatomic areas or subpopulations of cells, which is a 
phenomenon called "tropism". Examples are the preferential infection by HSV of the limbic 
system, and the infection of lower motor neurons by polio virus (Roos, 1999). 
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HSV type 1 produces the most common non-epidemic form of encephalitis with high 
mortality levels. The most common presenting symptoms are alterations in mood, memory, 
and behavior due in part to lesions in the limbic system, such as the inferior and medial 
regions of the temporal lobes, and the orbital gyri of the frontal lobes. Pathological changes of 
HSV encephalitis include neuronal necrosis and hemorrhagic regions in the brain, 
perivascular cuffing by inflammatory infiltrates, inclusion bodies, and microglial proliferation 
(Roos, 1999). 
 The passage of circulating lymphocytes into the CNS during acute viral encephalitis 
has been demonstrated to be mediated by adhesion molecules. Both ICAM-1 and VCAM-1 
are up-regulated on cerebrovascular endothelium during viral infection (Irani and Griffin, 
1996). The level of soluble ICAM-1 (Hartung et al., 1993) or ICAM-5 (telencephalin) 
(Rieckmann et al., 1998) in serum is also increased in viral encephalitis. Obviously, studies of 
these adhesion molecules will be helpful for diagnosis of the CNS encephalitis. 
 
3.2.2. Autoimmune diseases: multiple sclerosis (MS) 
 
Multiple sclerosis (MS), an autoimmune disease of the CNS, typically manifests 
between the ages of 20 and 40, and affects women twice as often as men. It is the major cause 
of neurological disability in young people in the Western hemisphere (reviewed by Bar-Or et 
al., 1999). 
MS results in permanent neurological dysfunction in many patients, due to destruction 
of myelin and axons and impaired regenerative capacity of oligodendrocytes. Variability in 
disease progression is a prominent clinical feature of MS. Some patients have initial attacks, 
complete recovery, and no further symptoms, while others progress rapidly and die within 
months of initial involvement. Most patients have remissions and exacerbations that occur 
during an unpredictable course. 
 Histologically, MS lesions are characterized by acute and/or chronic inflammation, 
glial cell activation, myelin destruction and loss of axons. Recent studies indicate that 
demyelination and oligodendrocyte death is mediated by infiltrating immune cells and by 
activated parenchymal CNS cells. Infiltrating immune cells consist mostly of T lymphocytes 
and monocytes. Both CD4
+
 and CD8
+
 T lymphocytes are present in MS lesions. Microglia in 
and around MS lesions become activated and transform into macrophages which phagocyte 
myelin (Bar-Or et al., 1999). 
Perivascular infiltration of inflammatory cells in the CNS represents one of the 
pathological hallmarks of MS lesions and requires adhesion and transmigration of these cells 
across the BBB (reviewed by Hickey, 1999). Elevated levels of ICAM-1 and VCAM-1 have 
been identified on endothelial cells of both acute and chronic MS lesions (Cannella and 
Raine, 1995). Their receptors (CD11a/CD18 and VLA-4, respectively) have also been 
identified on the perivascular inflammatory cells of MS lesions (Bo et al., 1996; Brosnan et 
al., 1995). Interactions between these adhesion molecules and their receptors have been 
implicated in the pathogenesis of EAE (Engelhardt et al., 1997; Yednock et al., 1992). In 
humans, studies have demonstrated adhesion molecules on the surface of CNS glial cells. 
ICAM-1 positive astrocytes are found both within and around active MS lesions, but not in 
normal brain (Brosnan et al., 1995). VCAM-1 and CD11a/CD18 are detectable on microglial 
cells in chronic MS lesions (Bo et al., 1996; Brosnan et al., 1995). In addition to the possible 
role in inflammatory cell migration, it has been proposed that glial cell expression of adhesion 
molecules may play roles in antigen presentation and T cell costimulation (Aloisi et al., 1998; 
Soos et al., 1998), and in glial-ECM interactions (Aloisi et al., 1992). 
As leukocyte accumulation at sites of inflammation involves a series of interactions 
between leukocytes and endothelial cells via adhesion molecules, use of antibodies or small 
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molecule therapy to block the molecular interactions that underlie leukocyte trafficking is 
viewed as a promising therapeutic approach for treating human MS diseases (Yednock et al., 
1992). Indeed, a recent short-term study of an anti-VLA-4 monoclonal antibody (Antegren, 
natalizumab) also demonstrated a reduction in new active and enhancing lesions during the 
first 12 weeks of follow-up of MS patients (Tubridy et al., 1999). 
 
4. INTERCELLULAR ADHESION MOLECULE-5 (ICAM-5, Telencephalin) 
 
4.1. Discovery 
 
During prenatal development of the mammalian CNS, the rostral portion of the neural 
tube gives rise to five segmental enlargements, telencephalon, diencephalon, mesencephalon, 
metencephalon, and myelencephalon, while the caudal part forms the spinal cord which is 
also composed of many segmental repeats. Of the five brain segments, telencephalon, the 
most rostral one, develops most remarkably and occupies the largest portion of the 
mammalian brain. It includes the cerebral neocortex, olfactory cortex, hippocampus, striatum, 
amygdala, septum, and olfactory bulb, and takes charge of higher functions of the brain such 
as memory, learning, sensory perception, and voluntary movements. 
In 1987, a Japanese group led by Dr. Kensaku Mori produced monoclonal antibodies 
against the dendrodendritic synaptosomal fraction of the rabbit olfactory bulb, in order to 
obtain specific immunohistochemical markers for mitral/tufted cells or granule cells. During 
the screening of the antibody library, they encountered an interesting one which exclusively 
labeled gray matter of all regions in the telencephalon, the most rostral portion of the brain, 
but not in the diencephalon, mesencephalon, metencephalon, or myelencephalon, the brain 
segments more caudal to the telencephalon (Mori et al., 1987).  
Three years later, using affinity chromatography with this monoclonal antibody, the 
Japanese group purified a membrane glycoprotein from the telencephalic regions of the rabbit 
brain, and gave it the name telencephalin (Oka et al., 1990). Since then, the cDNAs of rabbit 
(Yoshihara et al., 1994), mouse (Yoshihara et al., 1994), and human (Mizuno et al., 1997) 
telencephalin have been cloned. 
 
4.2. Properties 
 
The amino acid sequence of telencephalin from different species revealed that it is a 
type I integral membrane glycoprotein of 130 kDa, with a 107 kDa polypeptide composed of 
a signal peptide (26-27 amino acids), a large extracellular region (792-805 amino acids), a 
transmembrane region (28 amino acids), and a relatively short cytoplasmic tail (59-64 amino 
acids) (Fig. 4). The human telencephalin is highly homologous to rabbit and mouse 
telencephalin, with overall 84% and 85% amino acid sequence identities, respectively. The 
position of all cysteine residues, 28 in the extracellular region and 2 in the cytoplasmic region, 
is completely conserved in all the three species (Mizuno et al., 1997).   
The extracellular portion of telencephalin contains nine tandem repeats of C2-type Ig 
domains, rendering telencephalin a member of the IgSF. Human telencephalin contains 15 
putative N-linked glycosylation sites, and twelve of them are conserved in human, mouse, and 
rabbit telencephalin (Mizuno et al., 1997). The distal eight Ig domains of human telencephalin 
are closely related to those of ICAMs. The total amino acid identity is 50% with ICAM-1 
(domains 1-5), 55% with ICAM-3 (domains 1-5), 38% with ICAM-2 (domains 1-2), and 32% 
with ICAM-4 (domains 1-2). The highest homology is observed with the domain 2 of ICAM-
1 and the domains 2-4 of ICAM-3, with more than 64% amino acid identity (Fig. 4). Thus, 
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telencephalin is a novel member of the ICAM subgroup of the IgSF, and we have named it as 
ICAM-5.  
The genes encoding ICAM-1, -3, -4, and -5 have been mapped to human chromosome 
19p13.2 (Kilgannon et al., 1998). In particular, the ICAM-5 gene is in close vicinity to the 
ICAM-1 gene, with only a 5-kilobase interval, while the ICAM-3 gene is located 30-40 
kilobases downstream of ICAM-5. The human ICAM-5 gene is composed of 11 exons 
encoding the signal peptide, each of the nine extracellular domains, and with a single exon 
encoding both the transmembrane and the cytoplasmic domains. 
 
4.3. Expression 
 
As cited earlier, ICAM-5 is expressed exclusively in the telencephalon of mammalian 
brain (Oka et al., 1990). Within the telencephalon, the expression of ICAM-5 is restricted to 
certain types of neurons. For example, in the adult rabbit olfactory bulb, granule cells, but not 
mitral and tufted cells express ICAM-5 (Murakami et al., 1991); in the cat visual cortex, 
ICAM-5 is absent in neurons within layer IV, which receives massive afferent input from the 
thalamus, but is present in neurons of other cortical layers (Imamura et al., 1990); in the rat 
hippocampus, ICAM-5 expression is excluded from GABA- (γ-aminobutyric acid) ergic 
inhibitory interneurons, but is expressed in nealy all excitatory pyramidal neurons (Benson et 
al., 1998). 
At the subcellular level, ICAM-5 is localized exclusively to the soma-dendritic 
membrane of the neurons, but not to the axonal membrane (Benson et al., 1998). On cultured 
hippocampal neurons, ICAM-5 is expressed in dendritic growth cones and filopodia.  
The expression of ICAM-5 is developmentally regulated. In rodents, ICAM-5 is 
almost absent from embryonic brain, appears around birth, increases dramatically during the 
postnatal weeks, and continues to be expressed at a high level in the adult brain (Yoshihara et 
al., 1994). In human cerebrum, ICAM-5 appears in the hippocampus from the 29
th
 gestational 
week, and in the temporal cortex from the 35
th
 to 39
th
 gestational weeks, intensifies during the 
perinatal period, and persists into adulthood (Arii et al., 1999). Thus, the developmental 
appearance of ICAM-5 parallels the time of dendritic elongation and branching, and synapse 
formation in the telencephalon. 
 
4.4. Function 
 
So far, it is attractive to speculate that ICAM-5 might participate in the regulation of 
microglial activity through its binding to β2 integrins.  
  47 
AIMS OF THE STUDY 
 
ICAM-5 is a novel ICAM subfamily member of cell adhesion molecules, which is expressed 
exclusively in the CNS. Its function in the CNS has remained unclear. The aims of the present 
study were: 
 
1. To study its possible interactions with the leukocyte-specific β2 integrins. 
 
2. To characterize its interaction with the β2 integrin CD11a/CD18. 
 
3. To identifiy and characterize other adhesive interactions of ICAM-5. 
 
4. To study the mechanism of dendritic outgrowth promoted by ICAM-5. 
 
5. To study whether a soluble form of ICAM-5 exists in the cerebrospinal fluids (CSF) of 
patients with CNS disorders. 
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MATERIALS AND METHODS 
 
Detailed descriptions of the materials and methods are found in the original publications. 
 
 
Materials or Methods Original Publication 
1) Antibodies  I-IV 
2) CSF samples IV 
3) Cell culture I-IV 
4) Purification of integrins I 
5) Purification of ICAM-5 and ICAM-1 
recombinant proteins 
I-III 
6) SDS-PAGE I-IV 
7) Native-PAGE III 
8) Western Blot I-IV 
9) Immunoprecipitation I, II, IV 
10) Flow cytometry I, III 
11) Enzyme-linked immunosorbent assay I-IV 
12) Cell adhesion assays I, II, IV 
13) Viral binding assay IV 
14) Immunocytostaining II, III 
15) Immunohistochemical staining IV 
16) Neurite outgrowth assays III 
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RESULTS 
 
1. ICAM-5 is expressed in the somatodendritic region of cultured hippocampal neurons 
(III, unpublished data) 
 
Earlier immunohistochemical (Murakami et al., 1991) and immunocytochemical 
(Benson et al., 1998) studies of ICAM-5 have shown that ICAM-5 is localized to the 
somatodendritic region on mature telencephalic neurons. To verify this, we cultured rat 
embryonic hippocampal neurons on surface-coated poly-DL-ornithine for 2 weeks. We then 
made immunofluorescent staining of these neurons with both the dendritic marker anti-MAP-
2 and anti-ICAM-5 antibodies, as shown in Fig. 11. On embryonic neurons which had been 
cultured for only one day, MAP-2 was evenly distributed on cell bodies, and there was no 
expression of ICAM-5. However, on mature neurons which had been cultured for two weeks, 
both MAP-2 and ICAM-5 were co-expressed on the somatodendritic areas, but not on the 
axons. Similar results were obtained when hippocampal neurons were cultured on surfaces 
coated with purified ICAM-5 proteins (III, Fig. 7b). 
 
2. ICAM-5 is a cellular ligand for CD11a/CD18 (I, II) 
 
Based on the high amino acid sequence homology of ICAM-5 with ICAM-1 and 
ICAM-3, we tested the hypothesis that β2 integrins act as the receptors for ICAM-5. By using 
purified recombinant ICAM-5-Fc proteins, we found that the extracellular region of ICAM-5 
bound to integrin-bearing (I, Fig. 2) peripheral blood T lymphocytes (I, Fig. 3A), Jurkat T 
cells (I, Fig. 3B; II, Fig. 2), or lymphoblastoid B cells (I, Fig. 3C). The binding was 
temperature-, cation-, and activation-dependent (I, Fig. 4).  
 
Phase contrast          MAP-2               ICAM-5
 2-day
culture
2-week
culture
Axon
 
Figure 11. Immunocytostaining of cultured embryonic rat hippocampal neurons 
with anti-MAP-2 (red) and anti-ICAM-5 (green). Neurons cultured for 2 days in 
vitro do not express ICAM-5, however, after 2-week culture, ICAM-5 is 
expressed on the somatodendritic region of the neuron, but not on the axon 
(pinpointed by arrows). 
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By screening a panel of integrin-specific mAbs, we found that mAbs G43-25B (I, Fig. 
5B; II, Fig. 4) and TS1/22 (II, Fig. 4), which recognize the CD11a chain, blocked the binding 
of Jurkat T cell to purified ICAM-5. Moreover, mAb 7E4, which is against the CD18 chain, 
almost completely blocked the Jurkat cell binding (I, Fig. 5B; II, Fig. 4). The binding is 
ICAM-5-specific as mAbs against ICAM-5, namely TL-3, 179B, and 179I abolished the 
Jurkat cell binding (II, Fig. 3B). However mAbs against other integrins did not inhibit Jurkat 
or T lymphocyte binding to ICAM-5 (I, Fig. 5A and B), indicating that this interaction is 
mediated solely by CD11a/CD18.  
Further evidence of ICAM-5-CD11a/CD18 interaction include that ICAM-5-
transfected L cells bound to purified CD11a/CD18 (I, Fig. 6A), but not to purified 
CD11b/CD18 (I, Fig. 6B) or CD11c/CD18 (I, Fig. 6C), that ICAM-5-bearing hippocampal 
neurons bound to Jurkat cells (II, Fig. 7), and that both transfected L cell binding to purified 
CD11a7CD18 and hippocampal neuronal binding to Jurkat cells was specifically blocked by 
anti-CD11a/CD18 mAbs (I, Fig. 7; II, Fig. 7). 
 
3. The first amino-terminal Ig domain of ICAM-5 is involved in CD11a/CD18 binding 
(II) 
 
The binding regions for CD11a/CD18 in ICAM-1 (Staunton et al., 1990), ICAM-2 
(Casasnovas et al., 1999), and ICAM-3 (Holness et al., 1995) have all been mapped to their 
first Ig domains, although their second Ig domains are thought to be important in the 
presentation of the first domains. To identify the binding region of ICAM-5 for CD11a/CD18, 
we generated a series of recombinant ICAM-5-Fc constructs expressing different 
combinations of its extracellular nine Ig domains (II, Fig. 1).  
By performing cell adhesion assays with the plastic-coated ICAM-5 fusion proteins, 
we observed that ICAM-5 D1-Fc supported the binding of Jurkat cells at about 70% of the 
wild type level, which was significantly higher than Jurkat cell binding to control human IgG 
(II, Fig. 2). The binding of Jurkat cells to ICAM-5 D1-D2-Fc was slightly higher than to 
ICAM-5 D1-Fc. However, to fully recover the binding to wild type level, the first three 
domains were required. The binding was almost completely abrogated when the first or the 
first two domains were deleted (II, Fig.2). 
Furthermore, we produced a panel of mAbs against human ICAM-5, and mapped the 
epitops of these mAbs (II, Fig. 3A). We found three mAbs recognizing domain 1, namely TL-
1, 179B, and 179I, and domain 2, namely 179D, 179K, and 246E respectively; one mAb for 
domain 1-2, namely TL-1; and one for domain 3, namely 246K; two mAbs for domain 4-5, 
namely 246A and 246D. To examine whether the binding of human ICAM-5-Fc chimeric 
protein to Jurkat cells can be inhibited by the mAbs, the immobilized ICAM-5 D1-D9-Fc 
fusion protein was pretreated with the mAbs before adding CD11a/CD18-expressing Jurkat 
cells. We observed that the first domain recognizing mAbs, 179B, 179I, and TL-3, completely 
blocked the binding of Jurkat cells to ICAM-5 D1-D9-Fc, whereas the other mAbs only 
marginally reduced binding (II, Fig. 3B). The antibodies behaved in a similar way when we 
performed the experiments in the opposite direction where the mAbs were tested for the 
inhibition of binding of ICAM-5-transfected Paju cells to purified CD11a/CD18 (data not 
shown). These indicate that the first domain of ICAM-5 is important for CD11a/CD18 
binding. 
We have also mutated several residues in the first domain of ICAM-5, including 
glutamate
41
, corresponding to the glutamate
34
 residue in ICAM-1 and the glutamate
37
 residues 
in ICAM-2 and ICAM-3. This residue in ICAM-1-3 has been shown to be one of the most 
important binding sites for CD11a/CD18, and has been speculated to coordinate the metal 
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cation with the I domain of integrin. However, we failed to observe any effect of 
glutamate
41
/alanine mutation on ICAM-5 binding to CD11a/CD18 (unpublished result). 
 
4. Membrane-bound ICAM-5 exists in both monomeric and multimeric forms (III) 
 
Earlier studies of purified rabbit ICAM-5 by gel filtration indicated that ICAM-5 is a 
protein of 500 kDa consisting of four subunits each of 130 kDa. The four subunits are linked 
to each other without disulfide bonds (Oka et al., 1990). We also studied the human ICAM-5 
expressed on the cell surfaces of transfected Paju cells (III). By using native-PAGE, we 
observed that membrane-bound ICAM-5 mainly existed as a 550 kDa multimeric protein, 
probably a tetramer (III, Fig. 5b). Treating the cells with cytochalasin D brought most of the 
membranous human ICAM-5 into the monomeric form of 140 kDa (III, Fig. 5b). Treatment 
of the cells with soluble ICAM-5 D1-2-Fc protein also broke the ICAM-5 multimers into 
monomers (III, Fig. 5b). Moreover, we studied the expression of ICAM-5 during the 
development of rat brain. We found that in the first postnatal week of development, ICAM-5 
mainly existed as a monomer in the rat brain, and at the tenth day of postnatal development, a 
multimeric form corresponding in molecular weight to a tetramer began to appear (III, Fig. 
5a). In the adult rat brain, almost all ICAM-5 molecules are multimeric (III, Fig. 5a).  
 
5. Monomeric ICAM-5 can make homophilic binding (III) 
      
Our first hint that ICAM-5 could bind to itself homophilicly came from the 
observation that membrane-bound ICAM-5 partially colocalized at the cell-cell contact sites. 
This colocalization was abolished by treating the cells with mAbs against ICAM-5 (III, Fig. 
1). We therefore tested if the purified ICAM-5 protein can make homophilic interactions in 
vitro. For this purpose, we generated a series of truncated ICAM-5 proteins linked at their 
carboxyl-terminals to the Fc portion of human IgG1 (III, Fig. 2). 
By flow cytometric analysis, we found that recombinant proteins containing domains 
1-9, 1-5, 5-9, 6-9, 7-9, 6, and 7-8 ICAM-5-Fc proteins, as well as ICAM-1-Fc and NCAM-Fc 
proteins showed little binding to Paju-ICAM-5 cells. Truncated proteins containing domains 
1-4, 1-3, 1-2, 1, 2-5, 3-5, 4-5, 4, and 5, especially the domains 1-2 and 4-5 constructs, showed 
significant binding to Paju-ICAM-5 cells, but not to wild type Paju cells (III, Fig. 3). The 
results indicated that the homophilic interactions mainly involve the first five domains of 
ICAM-5, and the reason for the low binding of domains 1-9-Fc and domains 1-5-Fc proteins 
might be that these proteins were inhibited by intra-molecular association. 
Further support for homophilic interaction was obtained when we coated truncated, 
isolated ICAM-5-Fc proteins on plastic, and observed that biotinylated D1-2-Fc bound 
especially well to various constructs containing domains 4-5 (III, Fig. 4a). Moreover, we 
studied the effects of anti-ICAM-5 mAbs on the interaction of D1-2 with immobilized 
monomeric D1-9 (without Fc), and we observed that mAbs TL-3, 179B and 179I, recognizing 
D1, almost completely blocked the binding, while mAbs 179K, 179D and 246E (recognizing 
D2) were inactive or even increased binding (III, Fig. 4b). These data indicate that the 
homophilic interaction takes place mainly through the binding of the amino-terminal domain 
1 to domains 4-5.       
Evidence that multimeric ICAM-5 could block the homophilic binding was indirect. 
Even though we found the homophilic interactions of purified ICAM-5 proteins, we failed to 
observe any cell aggregation of ICAM-5-transfected Paju cells, which was also reported 
earlier with mouse ICAM-5-transfected L cells (Yoshihara et al., 1994). In addition, 
membrane-bound ICAM-5 was only partially localized at the cell-cell contact sites, while a 
large proportion of ICAM-5 molecules was concentrated at the uropods (III, Fig. 1b and f). 
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Based on these facts, and that membranous ICAM-5 mainly exists in multimeric form, we 
hypothesize that the cis association of ICAM-5 into multimers abolishes the trans homophilic 
interaction of monomeric ICAM-5. 
 
6. ICAM-5 mediates dendritic outgrowth by homophilic interaction (III) 
      
Since we observed the homophilic binding ability of ICAM-5, the next question was 
whether this ability has effect on neuronal activity. When we coated ICAM-5 D1-9-Fc on 
plastic, and then seeded Paju-WT or Paju-ICAM-5 cells, we observed neurites extending from 
Paju-ICAM-5 cells (III, Fig. 6b), but not from Paju-WT cells (III, Fig. 6a). When coated on 
ICAM-5 D1-2, the effect was more pronounced (III, Fig. 6d). In the presence of mAb 179B, 
the neurite extension from Paju-ICAM-5 cells was inhibited (III, Fig. 6f). We found 
significantly less neurites from either type of cells on ICAM-1-Fc coated surfaces (III, Fig. 6g 
and h) (III, Table II). 
We then tested if ICAM-5 is involved in the dendritic outgrowth using ICAM-5-
expressing rat hippocampal neurons, and rat cerebellar neurons lacking ICAM-5. By staining 
the neurons with the dendritic marker, MAP-2, and the axonal marker, tau, we found that rat 
hippocampal neurons were induced for dendritic outgrowth on surfaces coated with ICAM-5 
D1-9-Fc, D1-2-Fc, laminin, heparin-binding growth-associated molecule (HB-GAM), or 
poly-DL-ornithine (III, Fig. 7A), but not on ICAM-1-Fc. Interestingly, the morphology of 
dendrites induced by the different molecules was different from one another, with the most 
dramatic difference seen on ICAM-5 coated surfaces (III, Fig. 7a and b), which induced a 
network of dendritic arbors. When we calculated the number of major dendritic branches 
extending from the cell soma there was no significant difference in neurite induction by these 
molecules (with exception of ICAM-1). ICAM-5 (red) was strongly stained on neurons grown 
on ICAM-5 and little tau staining (green) was seen (III, Fig. 7b). In contrast, when neurons 
were coated on laminin, tau staining was more evident (III, Fig. 7b). Furthermore, the axonal 
arbors were more complex on laminin than on ICAM-5 (III, Fig. 7b, right), while the 
dendritic arbors were more extensive on ICAM-5 than on laminin (III, Fig. 7b, left). In 
comparison to hippocampal neurons, the cerebellar neurons, which do not express ICAM-5, 
showed significantly less capability of dendritic outgrowth on ICAM-5-coated surfaces than 
on the surfaces coated with the other molecules (III, Fig. 7c). 
To block the function of endogenous ICAM-5 expressed on hippocampal neurons, we 
coated with ICAM-5 D1-2-Fc and then incubated the hippocampal neurons with antibodies 
and soluble ICAMs in the culture medium. We found that an antiserum against rat ICAM-5, 
namely pAb 1000J, significantly inhibited dendritic outgrowth as compared with a control 
serum (III, Fig. 8a). Soluble ICAM-5 D1-2-Fc, but not ICAM-1-Fc, also showed a significant 
blocking effect. The effect of these proteins was quantitated (III, Fig.8b). 
 
7. Soluble ICAM-5 exists in the CSF, and is elevated in acute encephalitis, but not in 
MS (IV) 
 
Soluble form of ICAM-5 was recently found in normal human serum at a very low 
level (800 ± 800pg/ml), and was upregulated in the sera of patients with acute HSV 
encephalitis (122 ± 57ng/ml) (Rieckmann et al., 1998). At about the same time, we tested the 
soluble ICAM-5 in the CSF samples of patients with or without neurological disorders. We 
found that soluble ICAM-5 was significantly increased in the CSF of patients with acute 
encephalitis (320 ± 107ng/ml, n=25), as compared to patients with MS (128 ± 10ng/ml, n=16) 
and patients without neurological disorders (137 ± 6ng/ml, n=42) (IV, Fig. 2). In the acute 
encephalitis group, CSF soluble ICAM-5 concentrations were not related to the levels of CSF 
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total protein or neuron-specific enolase, which are markers of serum protein extravasation 
through leaking BBB and the extent of brain tissue damage. However, the levels of soluble 
ICAM-5 correlated significantly with the number of leukocytes (102 ± 33 x 106/l) found in the 
diagnostic CSF samples of the encephalitis patients (r=0.45, p=0.02, n=25). This correlation 
was stronger in a subgroup with virologically confirmed HSV encephalitis (r=0.94, p=0.001, 
n=7). 
The CSF samples from encephalitis were further immunoprecipitated with the mAb 
against human ICAM-5 (TL-3), and then immunoblotted by a pAb against the extracellular 
part of human ICAM-5. We found a protein of 115 kDa corresponding to the soluble form of 
ICAM-5, as compared with the 140 kDa membrane-bound ICAM-5 (IV, Fig. 3). 
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DISCUSSION 
 
1. ICAM-5-CD11a/CD18 interaction: role in leukocyte binding to neurons 
 
The first hint that ICAM-5 or telencephalin is a member of ICAM subgroup of IgSF 
came after its molecular cloning: Firstly, The Ig domains of ICAM-5 are most closely related 
to those of ICAM-1 and ICAM-3, and also show a weaker but significant homology to those 
of ICAM-2 and ICAM-4 (Mizuno et al., 1997). Secondly, the chromosomal locus of the 
human ICAM-5 gene was mapped to 19p13.2, in close vicinity of other ICAM genes, except 
ICAM-2 (Kilgannon et al., 1998). Hence, it was temping to speculate that ICAM-5 would 
share many properties with hitherto known ICAM members. 
In this study, we have shown that ICAM-5 is a ligand for CD11a/CD18 (LFA-1), by 
demonstrating that purified ICAM-5-Fc fusion proteins mediate leukocyte adhesion 
dependent on CD11a/CD18, and reciprocally that purified CD11a/CD18 mediates adhesion of 
cells expressing ICAM-5 (I, II). Besides, we have shown that ICAM-5-CD11a/CD18 
interaction mediates leukocyte binding to somatodendritic regions of hippocampal neurons 
(II).  
Leukocyte adhesion to purified ICAM-5 protein is temperature dependent, needs 
divalent cations, and can be increased by stimulation. These characteristics are typicial of 
integrin binding to their ligands. Addition of Mg
2+
, Mn
2+
, or PDBu substantially enhanced the 
binding of leukocytes to purified ICAM-5 protein, indicating that ICAM-5 recognizes both a 
high affinity state and a high avidity state of CD11a/CD18 (I). It is generally accepted that 
Mg
2+ 
and Mn
2+
 induce high affinity conformation of CD11a/CD18, while phorbol esters like 
PDBu induce a high avidity state of CD11a/CD18 (Kotovuori et al., 1999).   
Further studies of ICAM-5-CD11a/CD18 interactions indicate that the first domain of 
ICAM-5 is the most important region for CD11a/CD18. Further support for the pivotal role of 
the first domain in CD11a/CD18 binding is the finding that mAbs reacting with this domain 
completely inhibited adhesion of T lymphocytes to purified ICAM-5 and ICAM-5-expressing 
neurons. The slightly higher adhesion capacity of the longer domain 1 containing constructs 
could be due to more efficient presentation of the first domain. The other studied mAbs 
against ICAM-5 had no significant effects. Importantly, the efficient blocking of adhesion by 
the ICAM-5 mAbs indicates, but does not prove, that other ICAMs are not involved in 
binding of lymphocytes to neurons. 
Binding of ICAM-1 (Staunton et al., 1990), ICAM-2 (Casasnovas et al., 1999), 
ICAM-3 (Holness et al., 1995), and ICAM-4 (Hermand et al., 2000) to CD11a/CD18 have all 
been studied in molecular detail. The crystal structures of ICAM-1 (Bella et al., 1998; 
Casasnovas et al., 1998) and ICAM-2 (Casasnovas et al., 1997) have revealed similar, but 
distinct, structural properties of these two molecules. Of all the ICAMs studied so far, the first 
Ig domains are most important for binding to CD11a/CD18. However, their amino acid 
sequences are about 50 % homologous but only 26-30 % identical (Gahmberg et al., 1997). 
These facts may explain the overlapping, but distanct binding profiles of ICAM-CD11a/CD18 
interactions, not only in their affinities but also in their specificites (reviewed by Binnerts and 
van Kooyk, 1999). Thus, mAbs that block ICAM-1 binding to CD11a/CD18 do not affect 
ICAM-2 or ICAM-3 binding to CD11a/CD, and mAbs that stimulate CD11a/CD18 binding to 
ICAM-1 do not induce, or even inhibit CD11a/CD18 binding to ICAM-2 or ICAM-3 
(Binnerts et al., 1994; de Fougerolles et al., 1994). Moreover, the affinity of soluble ICAM-1 
binding to CD11a/CD18 was reported to be 9 times higher than that of soluble ICAM-3, and 
the molecules competed for binding to CD11a/CD18 (Woska et al., 1998). Similarly, in our 
study, the CD11a mAb G43-25B was able to completely block binding of ICAM-5-
transfected L cells to substrates coated with CD11a/CD18, whereas it was ineffective in 
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blocking the binding of ICAM-1-transfected L cells to CD11a/CD18. In addition, the mAb 
TS2/4 which blocks CD11a/CD18-ICAM-1 interaction did not inbibit the binding of 
CD11a/CD18 to ICAM-5. Furthermore, the mAb MEM83 enhanced the interaction of 
CD11a/CD18 with ICAM-1, but had no effect on the CD11a/CD18-ICAM-5 binding (I). 
Mutational studies on ICAM-1-3 have identified residues within the first Ig domains 
of these ICAM molecules which are crucial for binding to CD11a/CD18. The ICAM-1 and 
ICAM-2 crystal structures provide insight into the topology of these residues. Interestingly, a 
relatively flat binding surface on top of the first domain of ICAM-1 or ICAM-2 is exposed to 
the extracellular space through a bend in the connecting loop between domains 1 and 2, 
suggesting that residues on this binding face directly interact with CD11a/CD18. The possibly 
important residues, glutamate
37
 and glutamine
75
 in ICAM-2, glutamate
34
 and glutamine
73
 in 
ICAM-1, are found on this binding face, suggesting that these amino acids could be involved 
in direct interaction of ICAMs with CD11a/CD18, and supporting the hypothesis that this 
glutamate residue directly coordinates the Mg
2+
 in the I domain (Casasnovas et al., 1997; 
Casasnovas et al., 1998). Similarly, the position of the non-conserved tyrosine
54
 on the 
ICAM-2-binding face indicates that this amino acid directly contacts CD11a/CD18, while the 
position of threonine
38
 suggests that it contributes to ligand binding by positioning of the 
glutamate
37
 residue. However, the conserved amino acids serine
25
 and lysine
42
 are not located 
on the binding face, suggesting that these amino acids do not directly contribute to 
CD11a/CD18 binding (Casasnovas et al., 1997). By contrast, in the CD11a/CD18-ICAM-1 
interaction, it has been proposed that lysine
39
 of ICAM-1 interacts with glutamate
241
 in the I 
domain, suggesting that this lysine is exposed differently in ICAM-2 and ICAM-1 (McDowall 
et al., 1998). Finally, several non-conserved residues important for CD11a/CD18 binding of 
ICAM-1 (methionine
64
, tyrosine
66
 and asparagine
68
) and ICAM-3 (asparagine
23
, leucine
66
 and 
serine
68
) appear to be located on the ligand-binding face that coordinates the divalent cation in 
the I domain, as well as glutamate
37
 (ICAM-2) and glutamate
34
 (ICAM-1). Thus, these amino 
acids seem to directly contribute to adhesion. Based on this analysis, it is tempting to 
speculate that differences in the binding face on top of the first domains of ICAM-1 and -3, 
contribute to the different capacities of these ligands to support CD11a/CD18-mediated 
adhesion (Binnerts et al., 1994; de Fougerolles et al., 1994). 
Our unpublished data on site-directed mutations of ICAM-5 indicate, however, that 
the conserved glutamate
41
 residue does not seem to participate directly in CD11a/CD18 
binding, in contrast to ICAM-1-3. Interestingly, in the first domain of ICAM-4 (LW), the 
residue is replaced by an arginine
52
 residue which has an opposite electrical charge to the 
otherwise conserved glutamate residue, and recently published mutational study of ICAM-4 
suggests that mutation of this arginine residue back to glutamate does not have any effect on 
CD11a/CD18 binding. In contrast, four nonconserved residues, leucine
80
, tryptophan
93
 and 
arginine
97
 on the CFG face, and one tryptophan
77
 resideu on the E-F loop of domain 1 of 
ICAM-4 may contact CD11a/CD18 as part of the binding sites. These results demonstrate that 
different ICAM molecules have different capacities in their interactions with CD11a/CD18. 
ICAM-1 is expressed on the cell surface mostly as a dimer (Miller et al., 1995; Reilly 
et al., 1995). The crystal structure of the dimeric form of ICAM-1, containing only the first 
two Ig domains, provides additional evidence that dimerization of ICAM-1, and consequently 
CD11a/CD18, plays an important role in receptor-ligand interactions and downstream 
signalling (Casasnovas et al., 1998). By contrast, ICAM-2 and -3 dimerization has not been 
reported, and their artificial dimerization does not seem to be important for CD11a/CD18 
binding (Miller et al., 1995; Reilly et al., 1995). This explains why these ligands are less 
effective in supporting CD11a/CD18-mediated adhesion and suggests that other binding sites 
in the I domain of CD11a/CD18 are needed to stabilize interactions with ICAM-2 and -3 (van 
Kooyk et al., 1996).  
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In this study, a multimeric (probably tetrameric) form of membrane-bound ICAM-5 
was found (III). We have shown that multimeric ICAM-5 bound to CD11a/CD18 as well, 
because cells expressing ICAM-5 bound to purified CD11a/CD18 and CD11a/CD18-bearing 
T lymphocytes (I, II), and a majority of ICAM-5 proteins expressed on these cell surfaces are 
in multimeric forms (III). It seems that ICAM-5 has much lower affinity for CD11a/CD18 
than ICAM-1 (I), therefore, multimerization of the molecule would conceivably increase its 
binding ability for CD11a/CD18. However, we do not know yet whether the multimeric 
ICAM-5 has increased capacity for binding to CD11a/CD18, as compared to the monomeric 
ICAM-5, and this issue definitely needs future investigation. 
We have also identified, in this study, a soluble form of ICAM-5 in the human CSF, 
especially in patients with acut encephalitis (IV). The elevated level of soluble ICAM-5 
correlated well with the number of leukocytes in the CSF samples of acute encephalitis 
patients, but did not correlate with the leakage of BBB, indicating a possible role of soluble 
ICAM-5 in stimulating leukocyte extravasation into the CSF. Infected neurons may release 
ICAM-5 to stimulate lymphocytes migrating across a chemotactic gradient. Alternatively, 
neurons could release sICAM-5, which, at high concentrations, can prevent CD11a/CD18 
mediated binding of lymphocytes to diminish the deleterious effects of an aggravated immune 
response in the CNS.  
In addition, many members of the IgSF act as receptors for viruses, for example, 
ICAM-1 is a receptor for rhinovirus. The telencehalon, especially the hippocampus, of the 
human brain is a major target area of encephalitogenic viruses such as HSV, and 
encephalitogenic viruses might similarly recognize adhesion molecules on cerebral neurons. 
During encephalitis, sICAM-5 may be cleaved in a similar way to specifically influence viral 
attacks or regulate the viral binding of host cells.  
Thus far, the physiological role of ICAM-5-CD11a/CD18 interaction in the CNS has 
not been clarified. However, based on in vitro studies, several possible functions can be 
inferred:  
1) It is generally accepted that, during the development of mammalian brain, microglia 
derive from monocytes that infiltrate into the CNS. In the embryonic period of the rat, 
CD11a/CD18 immunoreactivity was displayed not only by intravascular blood cells but also 
by intraparenchymal round cells with a horseshoe-shaped nucleus, showing the typical 
morphological features of monocytes (Dalmau et al., 1997). Monocyte-like cells present in 
the embryonic brain parenchyma often displayed mitotic profiles. Immunohistochemical 
staining also revealed the presence of some CD11a/CD18-positive cells belonging to the 
ameboid microglial population (mostly from E18). In the postnatal period, CD11a/CD18 
immunoreactivity was displayed by some ameboid microglial cells (P0-P9) and also by some 
ramified microglia, and it was weaker in ramified microglia than in ameboid microglia. 
Several studies have demonstrated that interactions between CD11a/CD18 and its ligands, 
ICAM-1 and -2 which are expressed on the cerebral endothelial cells, are essential for the 
recruitment of microglial precursor cells (Dalmau et al., 1997; Rezaie et al., 1997). Since 
ICAM-5 is constitutively expressed on cerebral neurons, and since its expression mostly 
parallels the microglial appearance in the brain, ICAM-5 could induce further extravasation of 
CD11a/CD18-bearing microglial precursor cells into the brain parenchyma.  
2) ICAM-5 might be involved in the regulation of microglial activity. Microglia are 
considered to be the resident macrophages of the brain, usually resting in a normal state with 
a ramified appearance, but quickly becoming activated in response to even minor pathological 
changes in the brain (reviewed by Stoll and Jander, 1999). Microglial activation is associated 
with morphological change into an ameboid appearance, with retracted processes and a round 
cell body, accompanied by increased expression of several genes associated with the immune 
reaction, including CD11a/CD18 (Hailer et al., 1996). Activated microglia migrate toward 
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damaged neurons, proliferate, exhibit cytotoxic activity, and remove dead cells by 
phagocytosis (Stoll and Jander, 1999). Since neurons in the CNS are very sensitive to 
damage, and neuronal damage usually causes an eternal loss of viable neurons in the CNS, it 
is extremely important that microglial cells are kept in quiescent state under normal 
conditions. However, the mechanisms underlying the ramification of microglia remain largely 
unknown. In light of this, constitutive expression of ICAM-5 on neurons could inhibit the 
activation of microglia under normal conditions, and thus protect the neurons from 
unnecessary microglial attacks. A recent study showed that ICAM-5 induced an intensive 
spreading of microglia, accompanied by a clustering of CD11a/CD18 on microglial cell 
surfaces, implying that ICAM-5 may control the state and/or function of microglia under 
physiological conditions (Mizuno et al., 1999). Under pathological conditions, on the other 
hand, it is temping to argue that ICAM-5-CD11a/CD18 interaction may cause neuronal 
damage. However, even this possibility can not be ruled out, it is noteworthy that both ICAM-
1 and VCAM-1 have been reported to be expressed by stimulated human cerebral neurons, in 
response to cytokines, which mediate the neuronal binding of cytotoxic T lymphocytes 
(White et al., 1994), monocytes (Hery et al., 1995) or neutrophils (Birdsall et al., 1992). Both 
ICAM-1 and VCAM-1 are well-known high affinitive cellular ligands for β2 and β1 integrins 
respectively. Hence, ICAM-1 would perhaps compete with ICAM-5 for interaction 
CD11a/CD18 under pathological conditions. 
3) ICAM-5 could participate in the CNS immune privilege. The CNS has been 
regarded as an immunologically privileged site, but this does not necessarily mean immune 
preclusion. Immune privilege is an active process in which the CNS and the immune system 
collaborate in providing immune protection without the risk of immunopathogenic injury to 
the tissue itself. Activated T lymphocytes interact with astrocytes and microglial cells, which 
suppress T-cell activation and give apoptotic signals to infiltrating T lymphocytes through the 
Fas ligand/Fas pathway (reviewed by Gold, 1997). It is not yet known if neurons are able to 
actively induce apoptosis of T cells, but our findings that neurons can bind to the lymphocytes 
through the ICAM-5-CD11a/CD18 pathway makes it possible that neurons, by binding to T 
lymphcytes and presenting them to the neighboring glial cells, help glial cells to induce T-cell 
apoptosis. Indeed, binding between CD11a/CD18 and ICAM-1 has been reported to be 
essential for monocyte/macrophage-mediated T cell apoptosis (Zen et al., 1996) and T cell-
mediated B cell apoptosis in peripheral blood (Wang and Lenardo, 1997). 
4) It has recently been found that in the brains of patients with Alzheimer’s disease 
(AD), there was an upregulated expression of ICAM-5 on the neurites of surviving neurons 
around the amyloid plaques, although the average level of ICAM-5 in the neocortex and 
hippocampus of these patients was lower than that of controls (Hino et al., 1997). One 
hallmark of AD pathology is the accumulation of dystrophic neurites around these plaques 
together with newly proliferated glial cells and infiltrating immune cells (Akiyama et al., 
1993; Eikelenboom et al., 1994). These cells have been suggested to be important in synaptic 
stripping during CNS development and neuronal degeneration (Graeber et al., 1993). Taken 
together with our findings, these events indicate that the interaction between the integrin 
expressing immune cells and the ICAM-5 expressing neurons could be important in the 
synaptic reorgnization which takes place during normal CNS development and dystrophic 
neuritic outgrowth in AD. 
 
2. ICAM-5 homophilic interaction: role in dendritic elongation and arborization 
 
Neurons are known for their elaborate subcellular structures which enable the 
transmission of signals from one cell to another. To be meaningful they must make precise 
connections with their respective target cells. This developmental process includes axonal and 
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dendritic elongation, axonal guidance, and adhesive interactions between axonal growth cones 
and soma-dendritic membranes of target neurons that give rise to the formation of synaptic 
connections (reviewed by Brose, 1999). A number of factors are known to be involved in 
axonal guidance, including diffusible or surface-bound growth-promoting molecules and 
various adhesion moelcules, such as cadherins (Shapiro and Colman, 1999), integrins 
(Connolly and Tully, 1998), and members of IgSF (Walsh and Doherty, 1997). Among these 
several molecular pathways, neuron-neuron contact mediated by neuronal adhesion molecules 
of IgSF underlies an important way to influence brain architecture (Walsh and Doherty, 
1997).  
Since neurons are polarized, extending an axon and dendrites from the soma, neuronal 
cell adhesion molecules can be divided into axon-associated cell adhesion molecules 
(AxCAMs), such as NCAM, L1, and related molecules, and dendrite-associated cell adhesion 
molecules (DenCAMs) (Brummendorf and Rathjen, 1996; Yoshihara and Mori, 1994). While 
a great deal is known about the roles of AxCAMs in axonal elongation, fasciculation, and 
guidance by mechanisms involving transmembrane signaling pathways (reviewed by Crossin 
and Krushel, 2000; Walsh and Doherty, 1997), little is known about DenCAMs. However, 
DenCAMs are supposed to guide the formation of dendritic fasciculation and arborization, 
and to function as counter-receptors for AxCAMs in synaptogenesis. 
ICAM-5 has several features, which make it a candidate for a DenCAM: Firstly, it is 
localized to cell somata and dendrites of neurons, and neurons expressing ICAM-5 have more 
extensive dendritic branches than neurons without ICAM-5 (Benson et al., 1998). Secondly, it 
is expressed only in the telencephalon, the most rostral segment of the brain, and not in the 
caudal segments (Yoshihara et al., 1994). Thirdly, the onset of its expression temporally 
parallels the onset of dendritic elongation and synaptogenesis during the postnatal period 
(Imamura et al., 1990; Mori et al., 1987). These facts together support the hypothesis that 
ICAM-5 may provide a brain segment-specific cue for synaptogenesis or dendrite-dendrite 
interactions in the telencephalon. Indeed, earlier studies have shown that ICAM-5 promotes 
embryonic hippocampal neurite outgrowth (Tamada et al., 1998), and is involved in 
hippocampal long-term potentiation (Sakurai et al., 1998). However, the molecular basis has 
remained poorly understood. 
In this study, we described that ICAM-5 induces dendritic extension and branching 
through homophilic adhesion, the effect of which is dramatically different from that of 
laminin or HG-GAM, which are known to mainly promote axonal outgrowth, and that this 
activity can be blocked by mAbs against ICAM-5. Immunofluorescent studies by our group 
showed that ICAM-5 had a similar distribution as the dendritic marker MAP-2 (III).  MAP-2 
evidently also stained some axons on cultured hippocampal neurons (III, Fig. 7b), probably 
due to the fact that the neurons at this stage are not absolutely polarized. In contrast, axon 
staining with anti-tau showed a different distribution and little overlap was seen in cells 
grown on ICAM-5. When cultured on laminin, a number of tau
+
 neurites were seen. The 
stainings indicate that ICAM-5 promotes the expression of dendritic proteins, such as MAP-2, 
much better than laminin, whereas laminin promotes the expression of axonal proteins such as 
tau.  
The first indication of homophilic binding was obtained when we observed that 
ICAM-5 transfected in Paju cells was enriched at the cell-cell contact sites (III, Fig. 1). 
However, when we made the whole external part of ICAM-5 by recombinant methods, it did 
not show homophilic binding. This issue was then studied by making truncated shorter 
constructs of the molecule. We then found that the binding activity was mediated by 
homophilic binding of the NH2-terminal domain 1 to domains 4-5. Constructs containing 
domains 1-2 were more efficient in binding than the single first domain (III, Fig. 3 and 4). 
The finding that mAbs reacting with domain 2 did not inhibit binding further indicates that 
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domain 2 is not directly involved in binding. In fact, some antibodies to domain 2 enhanced 
binding, which could be due to conformational changes in domain 1. The reason for the 
inability of the isolated domains 1-9 construct to mediate binding could be its strong tendency 
to form higher aggregates, possibly tetramers in vitro. 
When we performed an analysis of the calculated pI values of the ICAM-5 
extracellular domains, we found that in all species of cloned ICAM-5, the pI values of 
domains 1-2 were around 11.3, while those of domains 4-5 were around 4.3, suggesting that 
the homophilic interaction of D1 with D4-5 could be, at least partially, mediated by 
electrostatic interactions between the respective domains. This characteristic of highly 
oppositely charged domains in ICAM-5 is unique among the ICAMs, which may be the 
reason that ICAM-1 did not show any homophilic binding, and neither did it bind ICAM-5, 
indicating that the homophilic binding of ICAM-5 is highly specific. 
Earlier studies on neuronal adhesion molecules have shown that the homophilic 
binding of NCAM involves all of the five Ig domains (Ranheim et al., 1996), whereas in the 
cases of L1 and cadherin, only Ig domain 2 in L1 (Zhao and Siu, 1995), and domain 1 in 
cadherin
 
(Tamura et al., 1998) are involved. The complex phenomena of homophilic binding 
of different cell adhesion molecules must underlie their different functions, not only in 
adhesion, but also in possible signaling events (Brummendorf and Rathjen, 1996). 
Even though we found the homophilic interactions of purified ICAM-5 proteins, we 
failed to observe any cell aggregation of ICAM-5-transfected Paju cells. Similar findings 
were earlier reported using mouse ICAM-5-transfected L cells (Yoshihara et al., 1994). In 
addition, membrane-bound ICAM-5 only partially colocalized at the cell-cell contact sites, 
while a large proportion of ICAM-5 molecules was concentrated at the uropods (III, Fig. 1b 
and f). Based on these facts, and that membranous ICAM-5 mainly exists in a multimeric 
form, we hypothesize that the cis association of ICAM-5 into multimers abolishes the trans 
homophilic interaction of monomeric ICAM-5. 
Multimerization of cell surface molecules is commonly believed to enhance the 
binding to their ligands/receptors through an increase in avidity. Such examples are the 
homodimerization of cadherin (Tamura et al., 1998), and ICAM-1
 
(Miller et al., 1995; Reilly 
et al., 1995), and heterodimerization of NgCAM and axonin-1
 
(Kunz et al., 1998). The 
behavior of ICAM-5 is different from that of the other studied Ig-domain containing adhesion 
proteins. We think that the inability of the ICAM-5 high molecular weight form to adhere is 
due to the fact that the homophilic binding of ICAM-5 requires a deeper accessibility of two 
opposite polypeptides. Furthermore, the studies with the truncated ICAM-5 molecules show 
that intramolecular associations may exist. The short constructs like domains 1-2 can bind 
because they have their binding domains accessible, whereas longer constructs like domains 
1-5 are inactive because of interpolypeptide association between domain 1 and domains 4-5.  
High local concentrations of ICAM-5 may promote high molecular weight complex 
formation as seen in Paju cells, where the uropods are especially rich in the protein. The non-
monomer state must not, however, be permanent in vivo because when Paju-ICAM-5 cells 
were incubated with truncated ICAM-5 fusion proteins containing the two NH2-terminal 
domains, the ICAM-5 molecules cells were brought into monomers (III, Fig. 5b). How this 
phenomenon is regulated in vivo remains unknown. When Paju-ICAM-5 cells were treated 
with cytochalasin D, ICAM-5 completely switched into monomers. These facts indicate a 
linkage of ICAM-5 with cytoskeletal proteins, as are other ICAM-molecules (see section 2 of 
this review). ICAM-5 was previously observed to concentrate in dendritic growth cones and 
filopodia in hippocampal neurons
 
(Benson et al., 1998). Experiments with cytochalasins to 
disrupt actin filaments within axonal growth cones have shown that the actin cytoskeleton is 
necessary for correct pathfinding in vivo, and for directed neurite outgrowth in vitro. The 
binding of adhesion molecules on the surface of cells may mediate changes in the cytoskeletal 
  60 
scaffold, thereby resulting in stabilized adhesion or forward growth
 
(reviewed by Suter and 
Forscher, 1998). The dynamic change of adhesiveness between monomers and multimers of 
ICAM-5, which may be regulated by the cytoskeleton, offers an interesting possibility to 
regulate the dendritic outgrowth. 
It has been known that dendritogenesis and synaptogenesis take place during the early 
postnatal period (reviewed by Brose, 1999). We therefore studied expression of ICAM-5 
during this time scale in rats where brain development has been extensively studied. 
Interestingly, during the first postnatal week, ICAM-5 mainly existed as a monomer, while 
within the postnatal 7-10 days, it gradually changed into a multimer. We do not know whether 
the multimeric form is a tetramer or a complex of ICAM-5 with other proteins. Nevertheless, 
this transition coincides with dendritogenesis in the early postnatal period of the rodent CNS. 
Obviously, it is important that when neurons extend branches of dendrites, they also 
need signals for distinguishing axonal growth cones from dendritic ones, so that the right 
synapses are formed. Based on our findings, we could envisage that, at an early stage of 
dendritogenesis, ICAM-5 monomers could promote dendritic elongation and arborization 
through homophilic interaction. When neurons become developmentally more mature, 
ICAM-5 mainly exists as multimers, whereby it does not promote dendrite-dendrite/soma 
interactions. It is also possible that the promotion of dendrite-dendrite adhesion by 
monomeric ICAM-5 does not promote dendritic branching, and conversely, that the non-
adhesive multimeric form could induce more dendritic branching. 
 
3. Relationship of ICAM-5 homophilic binding and integrin binding: changing 
partners in a molecular dance? 
 
We have shown that the first Ig domain of ICAM-5 binds to the β2 integrin 
CD11a/CD18, and this domain also mediates homophilic binding to domains 4-5. Although 
we do not yet know whether these two different bindings of ICAM-5 are located in 
overlapping regions of domain 1 or not, we did find that some mAbs which blocked the 
ICAM-5-integrin interaction also blocked the ICAM-5 homophilic binding (II, III). We also 
observed that, even though multimeric ICAM-5 did not support homophilic binding, it did 
have the ability to bind to CD11a/CD18. So    regulation of ICAM-5 homophilic binding by 
multimer/monomer transition could also be a means of influencing CD11a/CD18-ICAM-5 
interaction. 
To sum up our results, we have found that, firstly, ICAM-5 is a cellular ligand for the 
β2 integrin CD11a/CD18, and the binding is through its first amino-terminal domain; 
secondly, ICAM-5 binds in a homophilic manner through its domain 1 binding to domains 4-
5, and the homophilic binding mediates dendritic elongation; thirdly, ICAM-5 exists on cell 
membrane both as a monomer and as a multimer, and there is a transition of monomer to 
multimer during brain development; fourthly, multimeric ICAM-5 does not support 
homophilic binding, but supports CD11a/CD18 binding.  
Based on these observations, we would speculate that, as depicted in Fig. 12, in the 
early developing stage of the brain, monomeric ICAM-5 may be involved in dendritic 
elongation through trans homophilic binding, meanwhile, it could also participate in the 
extravasation of microglial precursor cells into brain parenchyma through binding to 
CD11a/CD18. As the brain develops, and the neurons become more mature, ICAM-5 is 
shifted into a multimer through cis extracellular interactions, multimeric ICAM-5 may not 
support trans homophilic binding any longer, so that the dendritic branching is facilitated, 
dendrite-dendritic interactions is prohibited, and the axon-dendritic interactions is favored. 
However, multimeric ICAM-5 may still bind to CD11a/CD18, and through this interaction, 
control the activities of microglia in the adult brain. 
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Figure 12. A model of the roles that ICAM-5 plays in the CNS. During 
the development of the CNS (A), monomeric ICAM-5 may promote 
dendritic outgrowth through homophilic binding, it may also induce the 
microglia migration through binding to CD11a/CD18 integrin. While in 
the adult brain (B), tetrameric ICAM-5 does not bind by homophilic 
interaction any longer, to facilitate the axon-dendrite interaction. 
Tetrameric ICAM-5 may still regulate the activities of microglia or 
infiltrating leukocytes. 
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CONCLUDING REMARKS 
 
As a novel cell adhesion molecule, ICAM-5 shares many structural similarities with 
the other members of IgSF, especially the ICAM subgroup. However, ICAM-5 has several 
unique properties as compared to the other ICAMs. The expression of ICAM-5 is confined to 
the telencephalic neurons of the CNS, whereas all the other ICAM members are expressed 
mostly by cells in the immune and blood systems, such as lymphocytes (ICAM-1-3), 
endothelial cells (ICAM-1 and -2), epithelial cells (ICAM-1), and erythrocytes (ICAM-4). 
Thus, although ICAM-5, like the other ICAMs, also binds to CD11a/CD18, and perhaps 
participates in immune-nervous system interactions, it could also participate, like NCAM and 
L1, in neuronal activity, such as neurite outgrowth, synaptogenesis, learning, and memory 
formation. Thus far, the ability of homophilic binding has only been ascribed to ICAM-5, but 
not the other ICAMs. This endows ICAM-5 a property shared mainly by the neuronal 
adhesion molecules. Nevertheless, ICAM-5 is also different from the neuronal adhesion 
molecules, in that it is a somatodendrite-specific adhesion molecule, whereas the others like 
NCAM and L1 are mainly axon-associated. In addition, the other neuronal adhesion 
molecules, with the exception of L1, have not been documented to play roles in the immune 
system. 
With its nine extracellular Ig domains, ICAM-5 is the largest member of ICAM 
subgroup identified so far. Therefore, it is much more complex than the other ICAMs. It will 
not be surprising if future investigations reveal more binding partners and other related 
functions of ICAM-5. 
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